{"id": "article-25401_0", "title": "Muscular Dystrophy -- Continuing Education Activity", "content": "Muscular dystrophy comprises a group of genetic disorders characterized by progressive muscle weakness and wasting, with a global incidence of approximately 1 in 5,000 individuals. While it can manifest at any age, it is most commonly diagnosed in childhood. The root cause of muscular dystrophy lies in mutations affecting genes responsible for muscle structure and function, leading to the gradual degeneration and loss of muscle fibers.", "contents": "Muscular Dystrophy -- Continuing Education Activity. Muscular dystrophy comprises a group of genetic disorders characterized by progressive muscle weakness and wasting, with a global incidence of approximately 1 in 5,000 individuals. While it can manifest at any age, it is most commonly diagnosed in childhood. The root cause of muscular dystrophy lies in mutations affecting genes responsible for muscle structure and function, leading to the gradual degeneration and loss of muscle fibers."}
{"id": "article-25401_1", "title": "Muscular Dystrophy -- Continuing Education Activity", "content": "Clinicians participating in this activity gain a comprehensive understanding of muscular dystrophy, including the global incidence, manifestation across ages, and the genetic basis involving mutations in muscle structure and function genes. The CE activity explores distinct hereditary patterns, emphasizing specific gene alterations leading to diverse manifestations. Participants learn about the impact on skeletal and cardiac muscles, disease progression, and associated complications, enhancing diagnostic and management skills for optimal patient care.", "contents": "Muscular Dystrophy -- Continuing Education Activity. Clinicians participating in this activity gain a comprehensive understanding of muscular dystrophy, including the global incidence, manifestation across ages, and the genetic basis involving mutations in muscle structure and function genes. The CE activity explores distinct hereditary patterns, emphasizing specific gene alterations leading to diverse manifestations. Participants learn about the impact on skeletal and cardiac muscles, disease progression, and associated complications, enhancing diagnostic and management skills for optimal patient care."}
{"id": "article-25401_2", "title": "Muscular Dystrophy -- Continuing Education Activity", "content": "Objectives: Identify the diverse pathophysiological mechanisms underlying various types of muscular dystrophy to enhance accurate and timely diagnoses. Differentiate between different forms of muscular dystrophy, considering their unique patterns of inheritance, onset timing, and rates of muscle degeneration. Implement a comprehensive multidisciplinary approach to care, integrating the expertise of different healthcare professionals for optimal patient management. Coordinate care efficiently, considering the unique needs and challenges associated with muscular dystrophy, to provide comprehensive and patient-centered support. Access free multiple choice questions on this topic.", "contents": "Muscular Dystrophy -- Continuing Education Activity. Objectives: Identify the diverse pathophysiological mechanisms underlying various types of muscular dystrophy to enhance accurate and timely diagnoses. Differentiate between different forms of muscular dystrophy, considering their unique patterns of inheritance, onset timing, and rates of muscle degeneration. Implement a comprehensive multidisciplinary approach to care, integrating the expertise of different healthcare professionals for optimal patient management. Coordinate care efficiently, considering the unique needs and challenges associated with muscular dystrophy, to provide comprehensive and patient-centered support. Access free multiple choice questions on this topic."}
{"id": "article-25401_3", "title": "Muscular Dystrophy -- Introduction", "content": "Muscular dystrophy constitutes a group of genetic disorders characterized by progressive muscle weakness and wasting.\u00a0Muscular Dystrophy\u00a0affects approximately 1 in 5,000 individuals worldwide and can manifest at any age, although it is most\u00a0frequently diagnosed\u00a0during childhood. The cause of muscular dystrophy\u00a0is\u00a0mutations\u00a0affecting genes responsible\u00a0for muscle structure and function,\u00a0resulting in progressive\u00a0degeneration and loss of muscle fibers.", "contents": "Muscular Dystrophy -- Introduction. Muscular dystrophy constitutes a group of genetic disorders characterized by progressive muscle weakness and wasting.\u00a0Muscular Dystrophy\u00a0affects approximately 1 in 5,000 individuals worldwide and can manifest at any age, although it is most\u00a0frequently diagnosed\u00a0during childhood. The cause of muscular dystrophy\u00a0is\u00a0mutations\u00a0affecting genes responsible\u00a0for muscle structure and function,\u00a0resulting in progressive\u00a0degeneration and loss of muscle fibers."}
{"id": "article-25401_4", "title": "Muscular Dystrophy -- Introduction", "content": "The term \"muscular dystrophy\"\u00a0encompasses a\u00a0spectrum of hereditary disorders leading to progressive and\u00a0widespread muscle disease\u00a0due to\u00a0inadequate or\u00a0absent glycoproteins in the muscle cell plasma membrane. [1] Muscular dystrophy\u00a0is a noncommunicable disorder with\u00a0numerous variations exhibiting unique patterns of inheritance, onset timing, and rate of muscle degeneration. [2] Distinct alterations in specific genes cause different manifestations of this disease.", "contents": "Muscular Dystrophy -- Introduction. The term \"muscular dystrophy\"\u00a0encompasses a\u00a0spectrum of hereditary disorders leading to progressive and\u00a0widespread muscle disease\u00a0due to\u00a0inadequate or\u00a0absent glycoproteins in the muscle cell plasma membrane. [1] Muscular dystrophy\u00a0is a noncommunicable disorder with\u00a0numerous variations exhibiting unique patterns of inheritance, onset timing, and rate of muscle degeneration. [2] Distinct alterations in specific genes cause different manifestations of this disease."}
{"id": "article-25401_5", "title": "Muscular Dystrophy -- Introduction", "content": "Muscular dystrophy affects skeletal and cardiac muscles. The progression of the condition varies depending on the type and severity of the disease but generally\u00a0follows a pattern of progressive muscle weakness,\u00a0reduced mobility, and the potential development of respiratory and cardiac complications.", "contents": "Muscular Dystrophy -- Introduction. Muscular dystrophy affects skeletal and cardiac muscles. The progression of the condition varies depending on the type and severity of the disease but generally\u00a0follows a pattern of progressive muscle weakness,\u00a0reduced mobility, and the potential development of respiratory and cardiac complications."}
{"id": "article-25401_6", "title": "Muscular Dystrophy -- Etiology", "content": "Muscular dystrophy can result from mutations in\u00a0various genes and\u00a0may be\u00a0inherited\u00a0in an X-linked, autosomal dominant, or autosomal recessive manner. [3] Changes in the X-linked gene DMD, which encodes dystrophin, are\u00a0the most frequent cause of muscular dystrophy. [4] This is why the phenotype is manifested in hemizygous males, as they have only a single copy of the X chromosome. [5] It is important to note that mutations in dystrophin also create allelic heterogeneity. [6] Mutations in the DMD gene, for example, may\u00a0give rise to either\u00a0Duchenne or the less\u00a0severe Becker muscular dystrophy,\u00a0depending on the extent of the lack of protein. [7]", "contents": "Muscular Dystrophy -- Etiology. Muscular dystrophy can result from mutations in\u00a0various genes and\u00a0may be\u00a0inherited\u00a0in an X-linked, autosomal dominant, or autosomal recessive manner. [3] Changes in the X-linked gene DMD, which encodes dystrophin, are\u00a0the most frequent cause of muscular dystrophy. [4] This is why the phenotype is manifested in hemizygous males, as they have only a single copy of the X chromosome. [5] It is important to note that mutations in dystrophin also create allelic heterogeneity. [6] Mutations in the DMD gene, for example, may\u00a0give rise to either\u00a0Duchenne or the less\u00a0severe Becker muscular dystrophy,\u00a0depending on the extent of the lack of protein. [7]"}
{"id": "article-25401_7", "title": "Muscular Dystrophy -- Etiology", "content": "Muscular dystrophy most often\u00a0results from defective or absent glycoproteins in the muscle membrane. [1] Various types of muscular dystrophy\u00a0are\u00a0associated with\u00a0distinct gene deletions or mutations,\u00a0giving rise to diverse\u00a0enzymatic or metabolic defects. [8] Notably, the\u00a0dystrophin gene is the largest in the human genome, with 79 exons. [9] Due to its immense size (>2 x 106 bases), the\u00a0dystrophin gene is\u00a0prone to a high rate of spontaneous mutations. [10]", "contents": "Muscular Dystrophy -- Etiology. Muscular dystrophy most often\u00a0results from defective or absent glycoproteins in the muscle membrane. [1] Various types of muscular dystrophy\u00a0are\u00a0associated with\u00a0distinct gene deletions or mutations,\u00a0giving rise to diverse\u00a0enzymatic or metabolic defects. [8] Notably, the\u00a0dystrophin gene is the largest in the human genome, with 79 exons. [9] Due to its immense size (>2 x 106 bases), the\u00a0dystrophin gene is\u00a0prone to a high rate of spontaneous mutations. [10]"}
{"id": "article-25401_8", "title": "Muscular Dystrophy -- Etiology", "content": "Insufficient levels of dystrophin result in damaged and ultimately dying muscle fibers, causing progressive muscle weakness, wasting, and fibrosis. This degenerative process can occur throughout the body, affecting various muscle groups and\u00a0giving rise\u00a0to different symptoms and complications.", "contents": "Muscular Dystrophy -- Etiology. Insufficient levels of dystrophin result in damaged and ultimately dying muscle fibers, causing progressive muscle weakness, wasting, and fibrosis. This degenerative process can occur throughout the body, affecting various muscle groups and\u00a0giving rise\u00a0to different symptoms and complications."}
{"id": "article-25401_9", "title": "Muscular Dystrophy -- Etiology", "content": "While the genetic mutations causing muscular dystrophy may differ, the underlying mechanism of muscle degeneration and loss\u00a0remains similar across all types of the disease. Early diagnosis, genetic testing, and appropriate management can help to improve outcomes and enhance the quality of life for individuals and families affected by muscular dystrophy.", "contents": "Muscular Dystrophy -- Etiology. While the genetic mutations causing muscular dystrophy may differ, the underlying mechanism of muscle degeneration and loss\u00a0remains similar across all types of the disease. Early diagnosis, genetic testing, and appropriate management can help to improve outcomes and enhance the quality of life for individuals and families affected by muscular dystrophy."}
{"id": "article-25401_10", "title": "Muscular Dystrophy -- Etiology", "content": "Although the phenotypic characteristics of\u00a0certain muscular dystrophies\u00a0are well-defined, the spectrum produced by mutations in various genes overlap,\u00a0leading\u00a0to nonallelic heterogeneity. [11] Recognizing\u00a0nonallelic heterogeneity is\u00a0crucial for\u00a0several reasons: The capacity to recognize disease loci in linkage studies is decreased by introducing subjects with associated phenotypes but separate genetic disorders. [12] Genetic testing becomes more complex\u00a0as\u00a0multiple\u00a0distinct genes need analysis along with the likelihood of\u00a0unique mutations in\u00a0each candidate gene. [12] Understanding how genes or proteins interact provides valuable insights into cell molecular physiology. [12]", "contents": "Muscular Dystrophy -- Etiology. Although the phenotypic characteristics of\u00a0certain muscular dystrophies\u00a0are well-defined, the spectrum produced by mutations in various genes overlap,\u00a0leading\u00a0to nonallelic heterogeneity. [11] Recognizing\u00a0nonallelic heterogeneity is\u00a0crucial for\u00a0several reasons: The capacity to recognize disease loci in linkage studies is decreased by introducing subjects with associated phenotypes but separate genetic disorders. [12] Genetic testing becomes more complex\u00a0as\u00a0multiple\u00a0distinct genes need analysis along with the likelihood of\u00a0unique mutations in\u00a0each candidate gene. [12] Understanding how genes or proteins interact provides valuable insights into cell molecular physiology. [12]"}
{"id": "article-25401_11", "title": "Muscular Dystrophy -- Etiology", "content": "Phenocopies can arise when nongenetic diseases simulate the symptoms of a genetic disorder. [13] For instance, features of virus- or toxin-induced neurologic symptoms\u00a0may resemble those\u00a0observed in muscular dystrophy. Like\u00a0nonallelic heterogeneity, phenocopies\u00a0pose challenges in linkage studies and genetic testing. [13] However, careful consideration of patient\u00a0history and accurate differentiation in phenotype can usually render signs that\u00a0distinguish these disorders from similar genetic diseases.\u00a0It is important to note that muscular dystrophy\u00a0exhibits variable expressivity and incomplete penetrance, contributing to its manifestations across a phenotypic spectrum in\u00a0different affected individuals,\u00a0highlighting the concept of\u00a0variable expressivity. [14]", "contents": "Muscular Dystrophy -- Etiology. Phenocopies can arise when nongenetic diseases simulate the symptoms of a genetic disorder. [13] For instance, features of virus- or toxin-induced neurologic symptoms\u00a0may resemble those\u00a0observed in muscular dystrophy. Like\u00a0nonallelic heterogeneity, phenocopies\u00a0pose challenges in linkage studies and genetic testing. [13] However, careful consideration of patient\u00a0history and accurate differentiation in phenotype can usually render signs that\u00a0distinguish these disorders from similar genetic diseases.\u00a0It is important to note that muscular dystrophy\u00a0exhibits variable expressivity and incomplete penetrance, contributing to its manifestations across a phenotypic spectrum in\u00a0different affected individuals,\u00a0highlighting the concept of\u00a0variable expressivity. [14]"}
{"id": "article-25401_12", "title": "Muscular Dystrophy -- Etiology -- Modes of Inheritance", "content": "Muscular dystrophy exhibits various modes of inheritance, including autosomal dominant, autosomal recessive, and X-linked patterns, with specific subtypes: Autosomal dominant, autosomal recessive, X-linked: Emery-Dreifuss Autosomal dominant, autosomal recessive Limb-Girdle (Dysferlinopathy, Erb) Pelvifemoral Scapulohumeral Autosomal dominant: Facioscapulohumeral (Landouzy-Dejerine) Late-onset distal (older than 40) Myotonic Oculopharyngeal Scapuloperoneal Autosomal recessive: Congenital Early onset distal (younger than 40) X-linked: Becker (benign pseudohypertrophic) Duchenne (pseudohypertrophic)", "contents": "Muscular Dystrophy -- Etiology -- Modes of Inheritance. Muscular dystrophy exhibits various modes of inheritance, including autosomal dominant, autosomal recessive, and X-linked patterns, with specific subtypes: Autosomal dominant, autosomal recessive, X-linked: Emery-Dreifuss Autosomal dominant, autosomal recessive Limb-Girdle (Dysferlinopathy, Erb) Pelvifemoral Scapulohumeral Autosomal dominant: Facioscapulohumeral (Landouzy-Dejerine) Late-onset distal (older than 40) Myotonic Oculopharyngeal Scapuloperoneal Autosomal recessive: Congenital Early onset distal (younger than 40) X-linked: Becker (benign pseudohypertrophic) Duchenne (pseudohypertrophic)"}
{"id": "article-25401_13", "title": "Muscular Dystrophy -- Etiology -- Autosomal dominant, autosomal recessive, X-linked:", "content": "Emery-Dreifuss muscular dystrophy:  Attributed to\u00a0an\u00a0X-linked recessive\u00a0defect in the nuclear protein emerin\u00a0at the Xq27-28 position. [15] This variant can also\u00a0arise from an autosomal recessive or autosomal dominant\u00a0defect in inner nuclear lamina proteins lamin A/C\u00a0on chromosome 1. [16]", "contents": "Muscular Dystrophy -- Etiology -- Autosomal dominant, autosomal recessive, X-linked:. Emery-Dreifuss muscular dystrophy:  Attributed to\u00a0an\u00a0X-linked recessive\u00a0defect in the nuclear protein emerin\u00a0at the Xq27-28 position. [15] This variant can also\u00a0arise from an autosomal recessive or autosomal dominant\u00a0defect in inner nuclear lamina proteins lamin A/C\u00a0on chromosome 1. [16]"}
{"id": "article-25401_14", "title": "Muscular Dystrophy -- Etiology -- Autosomal dominant, autosomal recessive inheritance:", "content": "Limb-Girdle Muscular Dystrophy:  Primarily exhibits\u00a0an autosomal recessive inheritance pattern but can\u00a0also occur in an autosomal dominant manner. [17] The age of onset varies, and the\u00a0distribution of involved muscles includes the limbs and trunk, often displaying a heterogeneous phenotype. [17] The recessive form of the disease tends to have an earlier onset and a more rapid progression, while the dominant form follows a slower and more variable course. [3]", "contents": "Muscular Dystrophy -- Etiology -- Autosomal dominant, autosomal recessive inheritance:. Limb-Girdle Muscular Dystrophy:  Primarily exhibits\u00a0an autosomal recessive inheritance pattern but can\u00a0also occur in an autosomal dominant manner. [17] The age of onset varies, and the\u00a0distribution of involved muscles includes the limbs and trunk, often displaying a heterogeneous phenotype. [17] The recessive form of the disease tends to have an earlier onset and a more rapid progression, while the dominant form follows a slower and more variable course. [3]"}
{"id": "article-25401_15", "title": "Muscular Dystrophy -- Etiology -- Autosomal dominant, autosomal recessive inheritance:", "content": "Multiple\u00a0genes have been implicated in this disease, with deficiencies identified in proteins such as sarcoglycan, calpain, dystroglycan, and dysferlin. [18] There is also potential involvement of\u00a0telethonin, lamin A/C, myotilin, and caveolin-3 (see Table. Limb-Girdle Muscular Dystrophy Subtype and Gene Abnormality). [19]", "contents": "Muscular Dystrophy -- Etiology -- Autosomal dominant, autosomal recessive inheritance:. Multiple\u00a0genes have been implicated in this disease, with deficiencies identified in proteins such as sarcoglycan, calpain, dystroglycan, and dysferlin. [18] There is also potential involvement of\u00a0telethonin, lamin A/C, myotilin, and caveolin-3 (see Table. Limb-Girdle Muscular Dystrophy Subtype and Gene Abnormality). [19]"}
{"id": "article-25401_16", "title": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:", "content": "Facioscapulohumeral muscular dystrophy:  Attributed to an\u00a0autosomal dominant\u00a0deletion of a 3.3 kb repeat on\u00a0chromosome 4. [32] Approximately\u00a095% of cases\u00a0result\u00a0from\u00a0a mutation in the D4Z4\u00a0region, leading to facioscapulohumeral muscular dystrophy 1. [33] Other areas, such as the SMCHD1 region in the type 2 subtype, can also cause this disease. [34] The age of onset is between 10\u00a0and 30 years,\u00a0and the distribution of affected muscles involved includes the face, neck, and shoulders. [33]", "contents": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:. Facioscapulohumeral muscular dystrophy:  Attributed to an\u00a0autosomal dominant\u00a0deletion of a 3.3 kb repeat on\u00a0chromosome 4. [32] Approximately\u00a095% of cases\u00a0result\u00a0from\u00a0a mutation in the D4Z4\u00a0region, leading to facioscapulohumeral muscular dystrophy 1. [33] Other areas, such as the SMCHD1 region in the type 2 subtype, can also cause this disease. [34] The age of onset is between 10\u00a0and 30 years,\u00a0and the distribution of affected muscles involved includes the face, neck, and shoulders. [33]"}
{"id": "article-25401_17", "title": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:", "content": "Myotonic muscular dystrophy:\u00a0Myotonic muscular dystrophy, or myotonic dystrophy, results from impaired dystrophia myotonica protein kinase\u00a0(DMPK) expression. [35] It is caused by an autosomal dominant, abnormally expanded CTG trinucleotide repeat sequence\u00a0located in the 3\u2032 untranslated region of the DMPK gene. [36] Due to the expansion of\u00a0trinucleotide repeat sequences (CTG),\u00a0a phenomenon\u00a0known as amplification and anticipation occurs, where family members develop the disease at\u00a0progressively\u00a0earlier ages across generations. [37] Clinical severity increases\u00a0with the number of nucleotide repeats, with some cases\u00a0involving\u00a0thousands of repeats. [38] The age of onset is approximately 10 to 15 years,\u00a0and the distribution of\u00a0affected muscles includes the face and extremities. This defect is classically associated with chromosome 19; however, a\u00a0second form can occur on chromosome 3q. [39] [40]", "contents": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:. Myotonic muscular dystrophy:\u00a0Myotonic muscular dystrophy, or myotonic dystrophy, results from impaired dystrophia myotonica protein kinase\u00a0(DMPK) expression. [35] It is caused by an autosomal dominant, abnormally expanded CTG trinucleotide repeat sequence\u00a0located in the 3\u2032 untranslated region of the DMPK gene. [36] Due to the expansion of\u00a0trinucleotide repeat sequences (CTG),\u00a0a phenomenon\u00a0known as amplification and anticipation occurs, where family members develop the disease at\u00a0progressively\u00a0earlier ages across generations. [37] Clinical severity increases\u00a0with the number of nucleotide repeats, with some cases\u00a0involving\u00a0thousands of repeats. [38] The age of onset is approximately 10 to 15 years,\u00a0and the distribution of\u00a0affected muscles includes the face and extremities. This defect is classically associated with chromosome 19; however, a\u00a0second form can occur on chromosome 3q. [39] [40]"}
{"id": "article-25401_18", "title": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:", "content": "Oculopharyngeal muscular dystrophy: Typical\u00a0onset around 30\u00a0to 40 years, with affected muscles including the extraocular and pharyngeal muscles. This condition is caused by an autosomal dominant\u00a0GCG trinucleotide repeat, resulting in deficient mRNA transfer from the nucleus. [41] Autosomal recessive inheritance:", "contents": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:. Oculopharyngeal muscular dystrophy: Typical\u00a0onset around 30\u00a0to 40 years, with affected muscles including the extraocular and pharyngeal muscles. This condition is caused by an autosomal dominant\u00a0GCG trinucleotide repeat, resulting in deficient mRNA transfer from the nucleus. [41] Autosomal recessive inheritance:"}
{"id": "article-25401_19", "title": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:", "content": "Congenital muscular dystrophy:  Caused by a\u00a0mutation\u00a0of the sarcolemmal protein merosin gene. Additionally, deficiencies or mutations in laminin-alpha 2, collagen type VI, integrin-alpha 7, and glycosyltransferases can contribute to the manifestation of this disorder. [42]", "contents": "Muscular Dystrophy -- Etiology -- Autosomal dominant inheritance:. Congenital muscular dystrophy:  Caused by a\u00a0mutation\u00a0of the sarcolemmal protein merosin gene. Additionally, deficiencies or mutations in laminin-alpha 2, collagen type VI, integrin-alpha 7, and glycosyltransferases can contribute to the manifestation of this disorder. [42]"}
{"id": "article-25401_20", "title": "Muscular Dystrophy -- Etiology -- X-linked inheritance:", "content": "Becker Muscular Dystrophy:\u00a0Caused by a mutation\u00a0in the\u00a0muscle protein dystrophin gene, which\u00a0codes for the protein dystrophin and is notably the largest in humans with\u00a079 exons. [8] The gene is transmitted in an\u00a0X-linked re\u00adcessive manner, located on the X chromosome's small arm (p) at the Xp21 locus position. [8] [43] In the absence of dystrophin, muscle cells deteriorate or die. The age of onset is 10 to 20 years,\u00a0and the distribution of involved muscles is generalized. [1]", "contents": "Muscular Dystrophy -- Etiology -- X-linked inheritance:. Becker Muscular Dystrophy:\u00a0Caused by a mutation\u00a0in the\u00a0muscle protein dystrophin gene, which\u00a0codes for the protein dystrophin and is notably the largest in humans with\u00a079 exons. [8] The gene is transmitted in an\u00a0X-linked re\u00adcessive manner, located on the X chromosome's small arm (p) at the Xp21 locus position. [8] [43] In the absence of dystrophin, muscle cells deteriorate or die. The age of onset is 10 to 20 years,\u00a0and the distribution of involved muscles is generalized. [1]"}
{"id": "article-25401_21", "title": "Muscular Dystrophy -- Etiology -- X-linked inheritance:", "content": "Duchenne muscular dystrophy:\u00a0Caused by a dystrophin gene mutation located on the small arm of the X chromosome at the Xp21 position. [8] A spontaneous mutation occurs in a third of cases, while X-linked maternal-fetal transmission accounts for two-thirds of cases. [44] [45] This mutation results in a nonfunctional dystrophin protein,\u00a0leading to effects similar to those observed\u00a0in Becker muscular dystrophy. The age of onset is\u00a0typically around 3 to 5 years,\u00a0and the distribution of involved muscles is generalized. [42]", "contents": "Muscular Dystrophy -- Etiology -- X-linked inheritance:. Duchenne muscular dystrophy:\u00a0Caused by a dystrophin gene mutation located on the small arm of the X chromosome at the Xp21 position. [8] A spontaneous mutation occurs in a third of cases, while X-linked maternal-fetal transmission accounts for two-thirds of cases. [44] [45] This mutation results in a nonfunctional dystrophin protein,\u00a0leading to effects similar to those observed\u00a0in Becker muscular dystrophy. The age of onset is\u00a0typically around 3 to 5 years,\u00a0and the distribution of involved muscles is generalized. [42]"}
{"id": "article-25401_22", "title": "Muscular Dystrophy -- Etiology -- X-linked inheritance:", "content": "In females with\u00a0Duchenne muscular dystrophy, an error in somatic cells\u00a0leads to the inactivation of\u00a01 X-chromosome at an early stage, creating a mosaic representation of heterozygous X-linked genes.\u00a0While this condition generally protects female heterozygotes from X-linked disorders affecting males, X-inactivation in the female carrier\u00a0with an X-autosome translocation can sometimes create a lethal genetic imbalance in half of the body's cells, causing cell death. Consequently, the same X-chromosome is expressed in every cell, and if\u00a0it\u00a0carries a disease allele, the individual can express the X-linked disease\u00a0similarly to\u00a0males. This phenomenon explains some\u00a0cases of Duchenne muscular dystrophy in females. [46]", "contents": "Muscular Dystrophy -- Etiology -- X-linked inheritance:. In females with\u00a0Duchenne muscular dystrophy, an error in somatic cells\u00a0leads to the inactivation of\u00a01 X-chromosome at an early stage, creating a mosaic representation of heterozygous X-linked genes.\u00a0While this condition generally protects female heterozygotes from X-linked disorders affecting males, X-inactivation in the female carrier\u00a0with an X-autosome translocation can sometimes create a lethal genetic imbalance in half of the body's cells, causing cell death. Consequently, the same X-chromosome is expressed in every cell, and if\u00a0it\u00a0carries a disease allele, the individual can express the X-linked disease\u00a0similarly to\u00a0males. This phenomenon explains some\u00a0cases of Duchenne muscular dystrophy in females. [46]"}
{"id": "article-25401_23", "title": "Muscular Dystrophy -- Epidemiology", "content": "Muscular dystrophy is a relatively rare condition, affecting an estimated 1 in every 5,000 to 10,000 individuals worldwide. In the\u00a0US, approximately 250,000 individuals are estimated to be living with muscular dystrophy or a related neuromuscular disorder. However, obtaining accurate prevalence estimates is challenging due to factors such as the wide range of disease severity,\u00a0variations in the age of onset, and the complexity of genetic testing required for diagnosis. Furthermore, the prevalence of the disease varies depending on the specific type of muscular dystrophy and the characteristics of the population being studied.", "contents": "Muscular Dystrophy -- Epidemiology. Muscular dystrophy is a relatively rare condition, affecting an estimated 1 in every 5,000 to 10,000 individuals worldwide. In the\u00a0US, approximately 250,000 individuals are estimated to be living with muscular dystrophy or a related neuromuscular disorder. However, obtaining accurate prevalence estimates is challenging due to factors such as the wide range of disease severity,\u00a0variations in the age of onset, and the complexity of genetic testing required for diagnosis. Furthermore, the prevalence of the disease varies depending on the specific type of muscular dystrophy and the characteristics of the population being studied."}
{"id": "article-25401_24", "title": "Muscular Dystrophy -- Epidemiology", "content": "Duchenne muscular dystrophy is the most common type of muscular dystrophy\u00a0observed in children, affecting approximately 1 in every 3,500 to 5,000 male births worldwide. Primarily affecting boys,\u00a0the onset of Duchenne muscular dystrophy typically occurs between the ages of 3 and 5 years.\u00a0The condition is progressive and ultimately fatal, with most individuals with Duchenne muscular dystrophy surviving into their\u00a0late teens or early 20s.", "contents": "Muscular Dystrophy -- Epidemiology. Duchenne muscular dystrophy is the most common type of muscular dystrophy\u00a0observed in children, affecting approximately 1 in every 3,500 to 5,000 male births worldwide. Primarily affecting boys,\u00a0the onset of Duchenne muscular dystrophy typically occurs between the ages of 3 and 5 years.\u00a0The condition is progressive and ultimately fatal, with most individuals with Duchenne muscular dystrophy surviving into their\u00a0late teens or early 20s."}
{"id": "article-25401_25", "title": "Muscular Dystrophy -- Epidemiology", "content": "Becker muscular dystrophy is a milder form resulting from mutations in the same DMD gene. This condition affects approximately 1 in every 18,000 to 30,000 individuals worldwide,\u00a0predominantly\u00a0males.\u00a0Becker muscular dystrophy typically has a later onset and milder course than Duchenne muscular dystrophy, with individuals often able to maintain ambulation into adulthood.", "contents": "Muscular Dystrophy -- Epidemiology. Becker muscular dystrophy is a milder form resulting from mutations in the same DMD gene. This condition affects approximately 1 in every 18,000 to 30,000 individuals worldwide,\u00a0predominantly\u00a0males.\u00a0Becker muscular dystrophy typically has a later onset and milder course than Duchenne muscular dystrophy, with individuals often able to maintain ambulation into adulthood."}
{"id": "article-25401_26", "title": "Muscular Dystrophy -- Epidemiology", "content": "Limb-girdle muscular dystrophy is a group of inherited muscular dystrophies that primarily impact the muscles of the hip and shoulder girdles.\u00a0Presently, there are over 30 subtypes of limb-girdle muscular dystrophy, each\u00a0arising\u00a0from gene mutations. The prevalence of\u00a0limb-girdle muscular dystrophy varies\u00a0based on the specific subtype, but it is estimated to be approximately 1 in every 14,500 to 123,000 individuals worldwide.", "contents": "Muscular Dystrophy -- Epidemiology. Limb-girdle muscular dystrophy is a group of inherited muscular dystrophies that primarily impact the muscles of the hip and shoulder girdles.\u00a0Presently, there are over 30 subtypes of limb-girdle muscular dystrophy, each\u00a0arising\u00a0from gene mutations. The prevalence of\u00a0limb-girdle muscular dystrophy varies\u00a0based on the specific subtype, but it is estimated to be approximately 1 in every 14,500 to 123,000 individuals worldwide."}
{"id": "article-25401_27", "title": "Muscular Dystrophy -- Epidemiology", "content": "Facioscapulohumeral muscular dystrophy is another type of muscular dystrophy that affects approximately 1 in every 20,000 individuals worldwide.\u00a0Facioscapulohumeral muscular dystrophy\u00a0typically\u00a0presents\u00a0with a later onset and slower progression than other types of muscular dystrophy, with symptoms often\u00a0emerging in the teenage or adult years. This condition is caused by mutations in the DUX4 gene, which\u00a0results in\u00a0inappropriate expression of a toxic protein in muscle cells.", "contents": "Muscular Dystrophy -- Epidemiology. Facioscapulohumeral muscular dystrophy is another type of muscular dystrophy that affects approximately 1 in every 20,000 individuals worldwide.\u00a0Facioscapulohumeral muscular dystrophy\u00a0typically\u00a0presents\u00a0with a later onset and slower progression than other types of muscular dystrophy, with symptoms often\u00a0emerging in the teenage or adult years. This condition is caused by mutations in the DUX4 gene, which\u00a0results in\u00a0inappropriate expression of a toxic protein in muscle cells."}
{"id": "article-25401_28", "title": "Muscular Dystrophy -- Epidemiology", "content": "Muscular dystrophy\u00a0more commonly affects males than females, as many genetic mutations responsible for the condition are on the X chromosome. However, some forms of muscular dystrophy, such as limb-girdle muscular dystrophy,\u00a0exhibit an equal prevalence in both males and females. This is outlined below as follows:", "contents": "Muscular Dystrophy -- Epidemiology. Muscular dystrophy\u00a0more commonly affects males than females, as many genetic mutations responsible for the condition are on the X chromosome. However, some forms of muscular dystrophy, such as limb-girdle muscular dystrophy,\u00a0exhibit an equal prevalence in both males and females. This is outlined below as follows:"}
{"id": "article-25401_29", "title": "Muscular Dystrophy -- Epidemiology -- Muscular dystrophy", "content": "Most common childhood muscular dystrophy:\u00a0Duchenne Most common adult muscular dystrophy:\u00a0Myotonic [47] Prevalence of muscular dystrophy (general population):\u00a016\u00a0to 25.1 per 100,000 [48] [49] Frequency of muscular dystrophy (general population): 1 per 3,000\u00a0to 8,000 [50] [51] Incidence of muscular dystrophy (male births):\u00a01 per 5,000 or 200 per 1,000,000 [52]", "contents": "Muscular Dystrophy -- Epidemiology -- Muscular dystrophy. Most common childhood muscular dystrophy:\u00a0Duchenne Most common adult muscular dystrophy:\u00a0Myotonic [47] Prevalence of muscular dystrophy (general population):\u00a016\u00a0to 25.1 per 100,000 [48] [49] Frequency of muscular dystrophy (general population): 1 per 3,000\u00a0to 8,000 [50] [51] Incidence of muscular dystrophy (male births):\u00a01 per 5,000 or 200 per 1,000,000 [52]"}
{"id": "article-25401_30", "title": "Muscular Dystrophy -- Epidemiology -- Becker muscular dystrophy", "content": "Prevalence (general population): 4.78 per 100,000 [53] Frequency (live male births): 1 per 18,000 [54] Incidence (live male births):\u00a01 per\u00a05618 [54]", "contents": "Muscular Dystrophy -- Epidemiology -- Becker muscular dystrophy. Prevalence (general population): 4.78 per 100,000 [53] Frequency (live male births): 1 per 18,000 [54] Incidence (live male births):\u00a01 per\u00a05618 [54]"}
{"id": "article-25401_31", "title": "Muscular Dystrophy -- Epidemiology -- Congenital muscular dystrophy", "content": "Prevalence (general population): 0.99 per 100,000 [53] Prevalence (children): 0.82 Per 100,000 [53] Prevalence (general population-Italy): 1 per 16,000 [55] Incidence (general population-Italy): 0.563\u00a0per 100,000 [56]", "contents": "Muscular Dystrophy -- Epidemiology -- Congenital muscular dystrophy. Prevalence (general population): 0.99 per 100,000 [53] Prevalence (children): 0.82 Per 100,000 [53] Prevalence (general population-Italy): 1 per 16,000 [55] Incidence (general population-Italy): 0.563\u00a0per 100,000 [56]"}
{"id": "article-25401_32", "title": "Muscular Dystrophy -- Epidemiology -- Duchenne muscular dystrophy", "content": "Prevalence (general population): 4.78 per 100,000 [53] Frequency (general population): 13\u00a0to 33 per 100,000 [57] Frequency (males): 1 per 3,500 [4] Incidence (live male births): 1 per 5,136 [52]", "contents": "Muscular Dystrophy -- Epidemiology -- Duchenne muscular dystrophy. Prevalence (general population): 4.78 per 100,000 [53] Frequency (general population): 13\u00a0to 33 per 100,000 [57] Frequency (males): 1 per 3,500 [4] Incidence (live male births): 1 per 5,136 [52]"}
{"id": "article-25401_33", "title": "Muscular Dystrophy -- Epidemiology -- Emery-Dreifuss muscular dystrophy", "content": "Prevalence (general population): 0.39 per 100,000 [53] Prevalence (children): 0.22 per 100,000 [53]", "contents": "Muscular Dystrophy -- Epidemiology -- Emery-Dreifuss muscular dystrophy. Prevalence (general population): 0.39 per 100,000 [53] Prevalence (children): 0.22 per 100,000 [53]"}
{"id": "article-25401_34", "title": "Muscular Dystrophy -- Epidemiology -- Facioscapulohumeral muscular dystrophy", "content": "Prevalence (general population): 3.95 per 100,000 [53] Prevalence (children): 0.29\u00a0per 100,000 [53]", "contents": "Muscular Dystrophy -- Epidemiology -- Facioscapulohumeral muscular dystrophy. Prevalence (general population): 3.95 per 100,000 [53] Prevalence (children): 0.29\u00a0per 100,000 [53]"}
{"id": "article-25401_35", "title": "Muscular Dystrophy -- Epidemiology -- Limb-Girdle muscular dystrophy", "content": "Prevalence (general population): 1.63 per 100,000 [53] Prevalence (children):\u00a00.48 per 100,000 [53]", "contents": "Muscular Dystrophy -- Epidemiology -- Limb-Girdle muscular dystrophy. Prevalence (general population): 1.63 per 100,000 [53] Prevalence (children):\u00a00.48 per 100,000 [53]"}
{"id": "article-25401_36", "title": "Muscular Dystrophy -- Epidemiology -- Myotonic muscular dystrophy", "content": "Prevalence (general population): 8.26 per 100,000 [53] Prevalence (Children): 1.41 per 100,000 [53]", "contents": "Muscular Dystrophy -- Epidemiology -- Myotonic muscular dystrophy. Prevalence (general population): 8.26 per 100,000 [53] Prevalence (Children): 1.41 per 100,000 [53]"}
{"id": "article-25401_37", "title": "Muscular Dystrophy -- Epidemiology -- Oculopharyngeal muscular dystrophy", "content": "Prevalence (general population): 0.13 per 100,000 [58] *US, England, Australia, & Canada unless otherwise specified*", "contents": "Muscular Dystrophy -- Epidemiology -- Oculopharyngeal muscular dystrophy. Prevalence (general population): 0.13 per 100,000 [58] *US, England, Australia, & Canada unless otherwise specified*"}
{"id": "article-25401_38", "title": "Muscular Dystrophy -- Pathophysiology", "content": "There are several types of muscular dystrophy, each\u00a0characterized by its unique\u00a0genetic mutation and pathophysiology. Nevertheless, all\u00a0forms of muscular dystrophy\u00a0share a common feature: the progressive loss of muscle mass and strength.", "contents": "Muscular Dystrophy -- Pathophysiology. There are several types of muscular dystrophy, each\u00a0characterized by its unique\u00a0genetic mutation and pathophysiology. Nevertheless, all\u00a0forms of muscular dystrophy\u00a0share a common feature: the progressive loss of muscle mass and strength."}
{"id": "article-25401_39", "title": "Muscular Dystrophy -- Pathophysiology", "content": "In addition to the absence of dystrophin, the pathophysiology of muscular dystrophy involves a cascade of events that lead to muscle fiber damage and loss. The\u00a0lack of dystrophin causes increased membrane permeability in muscle fibers,\u00a0enabling calcium ions to enter the cell and activate enzymes that degrade the muscle fiber structure. This inflammation and degeneration of muscle fibers\u00a0initiate a regeneration process by satellite cells. However, over time, this\u00a0regeneration becomes less efficient,\u00a0contributing to progressive muscle fiber loss and the development of fibrosis.", "contents": "Muscular Dystrophy -- Pathophysiology. In addition to the absence of dystrophin, the pathophysiology of muscular dystrophy involves a cascade of events that lead to muscle fiber damage and loss. The\u00a0lack of dystrophin causes increased membrane permeability in muscle fibers,\u00a0enabling calcium ions to enter the cell and activate enzymes that degrade the muscle fiber structure. This inflammation and degeneration of muscle fibers\u00a0initiate a regeneration process by satellite cells. However, over time, this\u00a0regeneration becomes less efficient,\u00a0contributing to progressive muscle fiber loss and the development of fibrosis."}
{"id": "article-25401_40", "title": "Muscular Dystrophy -- Pathophysiology", "content": "Typical findings in muscular dystrophy include muscle weakness and wasting, particularly in the proximal muscles of the lower limbs, pelvic girdle, and shoulders. Individuals affected by the condition\u00a0may encounter challenges in\u00a0movement, including running, jumping, and climbing stairs,\u00a0along with muscle cramps and stiffness.\u00a0With\u00a0disease progression, respiratory and cardiac complications may arise due to the\u00a0engagement\u00a0of muscles responsible for breathing and heart function.", "contents": "Muscular Dystrophy -- Pathophysiology. Typical findings in muscular dystrophy include muscle weakness and wasting, particularly in the proximal muscles of the lower limbs, pelvic girdle, and shoulders. Individuals affected by the condition\u00a0may encounter challenges in\u00a0movement, including running, jumping, and climbing stairs,\u00a0along with muscle cramps and stiffness.\u00a0With\u00a0disease progression, respiratory and cardiac complications may arise due to the\u00a0engagement\u00a0of muscles responsible for breathing and heart function."}
{"id": "article-25401_41", "title": "Muscular Dystrophy -- Pathophysiology -- Muscle Contraction", "content": "It is\u00a0crucial to grasp the fundamental physiology of muscle cell function initially. The sliding filament model represents muscle tension as a function dependent on the contraction of the muscle filaments. This contraction is facilitated by calcium released\u00a0from the sarcoplasmic reticulum,\u00a0leading to muscle depolarization. Intracellular calcium binds to the anionic charge of troponin C,\u00a0causing the\u00a0displacement of tropomyosin from the G-actin site. Once exposed, a myosin head attaches to the\u00a0exposed G-actin site, initiating a pivot that requires energy from adenosine triphosphate (ATP). This pivot allows actin filaments to slide past myosin filaments, resulting in muscle shortening, transmitted to the muscle cell's glycoprotein-rich cytoskeleton.", "contents": "Muscular Dystrophy -- Pathophysiology -- Muscle Contraction. It is\u00a0crucial to grasp the fundamental physiology of muscle cell function initially. The sliding filament model represents muscle tension as a function dependent on the contraction of the muscle filaments. This contraction is facilitated by calcium released\u00a0from the sarcoplasmic reticulum,\u00a0leading to muscle depolarization. Intracellular calcium binds to the anionic charge of troponin C,\u00a0causing the\u00a0displacement of tropomyosin from the G-actin site. Once exposed, a myosin head attaches to the\u00a0exposed G-actin site, initiating a pivot that requires energy from adenosine triphosphate (ATP). This pivot allows actin filaments to slide past myosin filaments, resulting in muscle shortening, transmitted to the muscle cell's glycoprotein-rich cytoskeleton."}
{"id": "article-25401_42", "title": "Muscular Dystrophy -- Pathophysiology -- Dystrophin", "content": "Dystrophin is\u00a0localized to the cytoplasmic surface of the muscle fiber plasma membrane, forming connections between the internal cytoskeleton\u00a0and the extracellular matrix\u00a0through glycoproteins that traverse the plasma membrane. [8] This cytoskeletal protein\u00a0provides structural stability to a protein (dystroglycan) complex within cell membranes. [59] Specifically, dystrophin anchors the actin cytoskeleton to the basement membrane within a membrane-glycoprotein complex. [59] Dystrophin, laminin, and other proteins constitute this cytoskeletal framework. [8] Dystrophin\u00a0interacts with F-actin and \u03b2-dystroglycan, binding to \u03b1-dystroglycan and laminin within the extracellular matrix. [8] [60] The primary role of dystrophin is to secure the cytoskeleton to the extracellular matrix, [8] and\u00a0any dysfunction in dystrophin alters tension transmission in contracting muscles. [1]", "contents": "Muscular Dystrophy -- Pathophysiology -- Dystrophin. Dystrophin is\u00a0localized to the cytoplasmic surface of the muscle fiber plasma membrane, forming connections between the internal cytoskeleton\u00a0and the extracellular matrix\u00a0through glycoproteins that traverse the plasma membrane. [8] This cytoskeletal protein\u00a0provides structural stability to a protein (dystroglycan) complex within cell membranes. [59] Specifically, dystrophin anchors the actin cytoskeleton to the basement membrane within a membrane-glycoprotein complex. [59] Dystrophin, laminin, and other proteins constitute this cytoskeletal framework. [8] Dystrophin\u00a0interacts with F-actin and \u03b2-dystroglycan, binding to \u03b1-dystroglycan and laminin within the extracellular matrix. [8] [60] The primary role of dystrophin is to secure the cytoskeleton to the extracellular matrix, [8] and\u00a0any dysfunction in dystrophin alters tension transmission in contracting muscles. [1]"}
{"id": "article-25401_43", "title": "Muscular Dystrophy -- Pathophysiology -- Dystrophin", "content": "When dystrophin is not functioning correctly, the contractile actin and myosin proteins, which generally shorten during muscle contraction, lead to both muscle weakness and injury to the cell membrane. This damage causes creatine kinase (CK) to leak\u00a0from every damaged muscle cell,\u00a0resulting in abnormally high levels\u00a0of CK in the plasma. [61] The release of CK incites an inflammatory response, promoting scar tissue formation and leading to the classic pseudohypertrophy of calf muscles\u00a0associated with muscular dystrophy. [62] Despite the appearance of hypertrophied muscles, there is a deficiency in functioning contractile filaments in the tissue, creating weak muscles. [1] The\u00ad deficit is present from fetal development onwards. [63] Phago\u00adcytosis of the damaged muscle cells by inflammatory cells\u00a0further contributes to scar\u00adring and impaired muscle function. [1]", "contents": "Muscular Dystrophy -- Pathophysiology -- Dystrophin. When dystrophin is not functioning correctly, the contractile actin and myosin proteins, which generally shorten during muscle contraction, lead to both muscle weakness and injury to the cell membrane. This damage causes creatine kinase (CK) to leak\u00a0from every damaged muscle cell,\u00a0resulting in abnormally high levels\u00a0of CK in the plasma. [61] The release of CK incites an inflammatory response, promoting scar tissue formation and leading to the classic pseudohypertrophy of calf muscles\u00a0associated with muscular dystrophy. [62] Despite the appearance of hypertrophied muscles, there is a deficiency in functioning contractile filaments in the tissue, creating weak muscles. [1] The\u00ad deficit is present from fetal development onwards. [63] Phago\u00adcytosis of the damaged muscle cells by inflammatory cells\u00a0further contributes to scar\u00adring and impaired muscle function. [1]"}
{"id": "article-25401_44", "title": "Muscular Dystrophy -- Pathophysiology -- Dystrophin-Glycoprotein Complex", "content": "This protein meshwork formed by dystrophin and associated proteins appears to strengthen the sarcolemma. [64] The loss of 1 component of this network may\u00a0trigger changes in other elements. For instance,\u00a0the initial loss of dystrophin may\u00a0result in the\u00a0breakdown of sarcoglycans, including\u00a0dystroglycan. [65] The\u00a0weakened\u00a0membrane ultimately leads to\u00a0muscle cell death. [1] Fat and connective tissue gradually replace skeletal muscle, resulting in significant muscle atrophy. [66] This skeletal muscle deterioration\u00a0leads to deformities in the skeleton, causing gradual immobility. Car\u00addiac and smooth muscle\u00a0in the gastrointestinal tract\u00a0commonly\u00a0undergo fibrosis. [67] The brain\u00a0may exhibit structural abnormalities with no\u00a0consistent\u00a0pattern. [67]", "contents": "Muscular Dystrophy -- Pathophysiology -- Dystrophin-Glycoprotein Complex. This protein meshwork formed by dystrophin and associated proteins appears to strengthen the sarcolemma. [64] The loss of 1 component of this network may\u00a0trigger changes in other elements. For instance,\u00a0the initial loss of dystrophin may\u00a0result in the\u00a0breakdown of sarcoglycans, including\u00a0dystroglycan. [65] The\u00a0weakened\u00a0membrane ultimately leads to\u00a0muscle cell death. [1] Fat and connective tissue gradually replace skeletal muscle, resulting in significant muscle atrophy. [66] This skeletal muscle deterioration\u00a0leads to deformities in the skeleton, causing gradual immobility. Car\u00addiac and smooth muscle\u00a0in the gastrointestinal tract\u00a0commonly\u00a0undergo fibrosis. [67] The brain\u00a0may exhibit structural abnormalities with no\u00a0consistent\u00a0pattern. [67]"}
{"id": "article-25401_45", "title": "Muscular Dystrophy -- Toxicokinetics", "content": "The toxicokinetics of muscular dystrophy involve complex interactions\u00a0among genetic, environmental, and immune factors, resulting in muscle weakness and degeneration. Additional research is needed to fully understand these mechanisms and develop more effective treatments for this debilitating condition.", "contents": "Muscular Dystrophy -- Toxicokinetics. The toxicokinetics of muscular dystrophy involve complex interactions\u00a0among genetic, environmental, and immune factors, resulting in muscle weakness and degeneration. Additional research is needed to fully understand these mechanisms and develop more effective treatments for this debilitating condition."}
{"id": "article-25401_46", "title": "Muscular Dystrophy -- Toxicokinetics -- Environmental Factors", "content": "Physical activity and nutrition\u00a0could potentially influence the\u00a0toxicokinetics of muscular dystrophy. Increased physical activity may elevate oxidative stress and inflammation, potentially worsening\u00a0muscle damage in individuals with muscular dystrophy.\u00a0Conversely, proper nutrition, with adequate protein and essential nutrients,\u00a0might contribute\u00a0to maintaining muscle mass and function.", "contents": "Muscular Dystrophy -- Toxicokinetics -- Environmental Factors. Physical activity and nutrition\u00a0could potentially influence the\u00a0toxicokinetics of muscular dystrophy. Increased physical activity may elevate oxidative stress and inflammation, potentially worsening\u00a0muscle damage in individuals with muscular dystrophy.\u00a0Conversely, proper nutrition, with adequate protein and essential nutrients,\u00a0might contribute\u00a0to maintaining muscle mass and function."}
{"id": "article-25401_47", "title": "Muscular Dystrophy -- Toxicokinetics -- Inflammation", "content": "Chronic inflammation\u00a0has the potential to\u00a0activate immune cells, release inflammatory cytokines, and promote muscle damage and degeneration. In some cases,\u00a0the accumulation of abnormal proteins in muscle cells may trigger inflammation.", "contents": "Muscular Dystrophy -- Toxicokinetics -- Inflammation. Chronic inflammation\u00a0has the potential to\u00a0activate immune cells, release inflammatory cytokines, and promote muscle damage and degeneration. In some cases,\u00a0the accumulation of abnormal proteins in muscle cells may trigger inflammation."}
{"id": "article-25401_48", "title": "Muscular Dystrophy -- Toxicokinetics -- Malignant Hyperthermia", "content": "This is a unique and life-threatening myopathy that can occur in genetically susceptive individuals following exposure to triggering factors,\u00a0typically halogenated anesthetic gases like halothane, isoflurane, sevoflurane, and desflurane. [68] Additionally, exposure to succinylcholine can also induce this condition. [69] In\u00a0individuals with dystrophinopathies, the administration of these agents can lead\u00a0to rhabdomyolysis, prompting many experts to advocate for the exclusive use of nontriggering agents.", "contents": "Muscular Dystrophy -- Toxicokinetics -- Malignant Hyperthermia. This is a unique and life-threatening myopathy that can occur in genetically susceptive individuals following exposure to triggering factors,\u00a0typically halogenated anesthetic gases like halothane, isoflurane, sevoflurane, and desflurane. [68] Additionally, exposure to succinylcholine can also induce this condition. [69] In\u00a0individuals with dystrophinopathies, the administration of these agents can lead\u00a0to rhabdomyolysis, prompting many experts to advocate for the exclusive use of nontriggering agents."}
{"id": "article-25401_49", "title": "Muscular Dystrophy -- Toxicokinetics -- Malignant Hyperthermia", "content": "Malignant hyperthermia\u00a0occurs due\u00a0to\u00a0abnormal calcium\u00a0regulation\u00a0associated with dystropinopathies. Dysregulated calcium release of the sarcoplasmic reticulum, coupled with anesthetic-induced interference\u00a0in calcium reuptake, results in\u00a0persistent muscle contraction, prolonged aerobic and anaerobic metabolism, increased carbon dioxide production, elevated end-tidal carbon dioxide, and tachycardia in these individuals who are unable to increase their alveolar minute volume adequately. This hypermetabolism generates an exponentially dangerous amount of heat, overwhelming the body's capacity to dissipate it effectively.", "contents": "Muscular Dystrophy -- Toxicokinetics -- Malignant Hyperthermia. Malignant hyperthermia\u00a0occurs due\u00a0to\u00a0abnormal calcium\u00a0regulation\u00a0associated with dystropinopathies. Dysregulated calcium release of the sarcoplasmic reticulum, coupled with anesthetic-induced interference\u00a0in calcium reuptake, results in\u00a0persistent muscle contraction, prolonged aerobic and anaerobic metabolism, increased carbon dioxide production, elevated end-tidal carbon dioxide, and tachycardia in these individuals who are unable to increase their alveolar minute volume adequately. This hypermetabolism generates an exponentially dangerous amount of heat, overwhelming the body's capacity to dissipate it effectively."}
{"id": "article-25401_50", "title": "Muscular Dystrophy -- History and Physical", "content": "The onset of muscular dystrophy usually occurs\u00a0in the third\u00a0to fourth decades of life. [47] However, it may\u00a0also become apparent in infancy or\u00a0undergo accelerated deterioration near onset. [39] Parents of affected individuals may\u00a0express concerns\u00a0about their child's walking ability compared to peers of the same age. [70] [71] The child may\u00a0encounter difficulties in activities like kicking a ball due to muscle weakness. [72] Pseudo-drop events\u00a0resulting from weakness of the quadriceps muscle may also be observed. [73] Notably, both\u00a0parents could be in good health. [74]", "contents": "Muscular Dystrophy -- History and Physical. The onset of muscular dystrophy usually occurs\u00a0in the third\u00a0to fourth decades of life. [47] However, it may\u00a0also become apparent in infancy or\u00a0undergo accelerated deterioration near onset. [39] Parents of affected individuals may\u00a0express concerns\u00a0about their child's walking ability compared to peers of the same age. [70] [71] The child may\u00a0encounter difficulties in activities like kicking a ball due to muscle weakness. [72] Pseudo-drop events\u00a0resulting from weakness of the quadriceps muscle may also be observed. [73] Notably, both\u00a0parents could be in good health. [74]"}
{"id": "article-25401_51", "title": "Muscular Dystrophy -- History and Physical", "content": "During a\u00a0physical examination, individuals affected by muscular dystrophy\u00a0typically\u00a0exhibit pronounced calf muscle enlargement along with weakness in the proximal muscles of the lower limbs. [75] Consequently, affected individuals often rely on\u00a0their arms and hands\u00a0for assistance when\u00a0rising from a seated position. [76] Other complaints include a history of delayed ambulation, toe walking, calf hypertrophy, and proximal hip girdle muscle instability. [77]", "contents": "Muscular Dystrophy -- History and Physical. During a\u00a0physical examination, individuals affected by muscular dystrophy\u00a0typically\u00a0exhibit pronounced calf muscle enlargement along with weakness in the proximal muscles of the lower limbs. [75] Consequently, affected individuals often rely on\u00a0their arms and hands\u00a0for assistance when\u00a0rising from a seated position. [76] Other complaints include a history of delayed ambulation, toe walking, calf hypertrophy, and proximal hip girdle muscle instability. [77]"}
{"id": "article-25401_52", "title": "Muscular Dystrophy -- History and Physical", "content": "Presentations may also\u00a0include asymptomatic elevation of serum creatine kinase (CK), exertion intolerance, dilated cardiomyopathy, malignant hyperthermia, quadriceps myopathy, language delay, and in rare cases, Turner syndrome in X chromosome monozygotic females with Duchenne muscular dystrophy. [78] In some individuals with subclinical muscular dystrophy, the diagnosis may initially be suspected\u00a0based on family history or the\u00a0presence of\u00a0elevated liver enzymes. However, the underlying cause of these enzyme elevations is not always clear. [79] These enzymes may include alanine aminotransferase and aspartate aminotransferase. [79]", "contents": "Muscular Dystrophy -- History and Physical. Presentations may also\u00a0include asymptomatic elevation of serum creatine kinase (CK), exertion intolerance, dilated cardiomyopathy, malignant hyperthermia, quadriceps myopathy, language delay, and in rare cases, Turner syndrome in X chromosome monozygotic females with Duchenne muscular dystrophy. [78] In some individuals with subclinical muscular dystrophy, the diagnosis may initially be suspected\u00a0based on family history or the\u00a0presence of\u00a0elevated liver enzymes. However, the underlying cause of these enzyme elevations is not always clear. [79] These enzymes may include alanine aminotransferase and aspartate aminotransferase. [79]"}
{"id": "article-25401_53", "title": "Muscular Dystrophy -- History and Physical", "content": "Given\u00a0the X-linked inheritance pattern of\u00a0muscular dystrophy, the overwhelming majority of patients are male. [4] Symptomatic disease in daughters\u00a0can be\u00a0explained by factors such as Turner syndrome, skewed X chromosome inactivation, translocation of the mutated gene to an autosome, or uniparental disomy (both copies of a chromosome set originating from one parent). [80] Typically, symptomatic females present in infancy with proximal muscle weakness. [81] Reports exist of increased weakness in adulthood, myalgias, spasms, and lethargy as initial manifestations. [75] Scoliosis and sustained alveolar hypoventilation can cause severe problems for every child with muscular dystrophy. [82]", "contents": "Muscular Dystrophy -- History and Physical. Given\u00a0the X-linked inheritance pattern of\u00a0muscular dystrophy, the overwhelming majority of patients are male. [4] Symptomatic disease in daughters\u00a0can be\u00a0explained by factors such as Turner syndrome, skewed X chromosome inactivation, translocation of the mutated gene to an autosome, or uniparental disomy (both copies of a chromosome set originating from one parent). [80] Typically, symptomatic females present in infancy with proximal muscle weakness. [81] Reports exist of increased weakness in adulthood, myalgias, spasms, and lethargy as initial manifestations. [75] Scoliosis and sustained alveolar hypoventilation can cause severe problems for every child with muscular dystrophy. [82]"}
{"id": "article-25401_54", "title": "Muscular Dystrophy -- History and Physical -- Arrhythmias", "content": "Cardiac arrhythmias have\u00a0greater\u00a0significance in individuals\u00a0with muscular dystrophy. The typical electrocardiogram (ECG) shows increased net RS in lead V1, deep and narrow Q waves\u00a0in the precordial leads,\u00a0and tall right precordial R waves in V1. [83] Cardiac disturbances\u00a0are commonly observed in patients with Duchenne muscular dystrophy type 1. [84]", "contents": "Muscular Dystrophy -- History and Physical -- Arrhythmias. Cardiac arrhythmias have\u00a0greater\u00a0significance in individuals\u00a0with muscular dystrophy. The typical electrocardiogram (ECG) shows increased net RS in lead V1, deep and narrow Q waves\u00a0in the precordial leads,\u00a0and tall right precordial R waves in V1. [83] Cardiac disturbances\u00a0are commonly observed in patients with Duchenne muscular dystrophy type 1. [84]"}
{"id": "article-25401_55", "title": "Muscular Dystrophy -- History and Physical -- Arrhythmias", "content": "Myotonic dystrophy also affects the heart muscle, causing arrhythmias and heart block. [85] ECG abnormalities include first-degree heart block and more extensive conduction system involvement. A complete heart block and sudden death can occur. [86] Congestive heart failure", "contents": "Muscular Dystrophy -- History and Physical -- Arrhythmias. Myotonic dystrophy also affects the heart muscle, causing arrhythmias and heart block. [85] ECG abnormalities include first-degree heart block and more extensive conduction system involvement. A complete heart block and sudden death can occur. [86] Congestive heart failure"}
{"id": "article-25401_56", "title": "Muscular Dystrophy -- History and Physical -- Arrhythmias", "content": "Congestive heart failure\u00a0is rare in muscular dystrophy, typically occurring only in cases of severe stress, such as pneumonia. [87] Infrequent instances of congestive heart failure may result from cor pulmonale secondary to respiratory failure. [88] Additionally, mitral valve prolapse\u00a0is a common occurrence in individuals with\u00a0muscular dystrophy. [88] Dilated c ardiomyopathy", "contents": "Muscular Dystrophy -- History and Physical -- Arrhythmias. Congestive heart failure\u00a0is rare in muscular dystrophy, typically occurring only in cases of severe stress, such as pneumonia. [87] Infrequent instances of congestive heart failure may result from cor pulmonale secondary to respiratory failure. [88] Additionally, mitral valve prolapse\u00a0is a common occurrence in individuals with\u00a0muscular dystrophy. [88] Dilated c ardiomyopathy"}
{"id": "article-25401_57", "title": "Muscular Dystrophy -- History and Physical -- Arrhythmias", "content": "Genetic dilated cardiomyopathies, accounting for 30% to 40% of nonischemic dilated cardiomyopathies, are associated with some cases of muscular dystrophy. [89] In the skeletal myopathies, an ECG will reveal a dominant R wave in lead V1\u00a0(indicative of prominent posterior wall involvement). [90] While the presence of cardiomyopathy is prevalent in almost all patients with muscular dystrophy, a cardiac cause of death is not always certain. [91] The incidence of cardiac involvement in Duchenne muscular dystrophy is as high as 95%. [92] Chronic heart failure may occur in 50% of children. [93]", "contents": "Muscular Dystrophy -- History and Physical -- Arrhythmias. Genetic dilated cardiomyopathies, accounting for 30% to 40% of nonischemic dilated cardiomyopathies, are associated with some cases of muscular dystrophy. [89] In the skeletal myopathies, an ECG will reveal a dominant R wave in lead V1\u00a0(indicative of prominent posterior wall involvement). [90] While the presence of cardiomyopathy is prevalent in almost all patients with muscular dystrophy, a cardiac cause of death is not always certain. [91] The incidence of cardiac involvement in Duchenne muscular dystrophy is as high as 95%. [92] Chronic heart failure may occur in 50% of children. [93]"}
{"id": "article-25401_58", "title": "Muscular Dystrophy -- History and Physical -- Musculoskeletal Findings", "content": "Research findings\u00a0suggest that the\u00a0gracilis, semimembranosus, semitendinosus, and sartorius muscles can be\u00a0affected in patients with muscular dystrophy. [94] Additionally, individuals may\u00a0exhibit an equinovarus feet deformity, [95] pelvic tilting, [73] and contractures throughout the body. [96] Furthermore, spinal deformities may\u00a0lead to conditions such as\u00a0lordosis or scoliosis, [97] and\u00a0ocular issues like\u00a0cataracts and bilateral ptosis can also occur. [98]", "contents": "Muscular Dystrophy -- History and Physical -- Musculoskeletal Findings. Research findings\u00a0suggest that the\u00a0gracilis, semimembranosus, semitendinosus, and sartorius muscles can be\u00a0affected in patients with muscular dystrophy. [94] Additionally, individuals may\u00a0exhibit an equinovarus feet deformity, [95] pelvic tilting, [73] and contractures throughout the body. [96] Furthermore, spinal deformities may\u00a0lead to conditions such as\u00a0lordosis or scoliosis, [97] and\u00a0ocular issues like\u00a0cataracts and bilateral ptosis can also occur. [98]"}
{"id": "article-25401_59", "title": "Muscular Dystrophy -- History and Physical -- Contractures", "content": "Most patients\u00a0with muscular dystrophy experience joint contractures of varying degrees, affecting the elbows, hips, knees, and ankles.\u00a0Arthrogryposis, or joint contractures present at birth, can occur.\u00a0Contractures of the heel cords and iliotibial bands manifest by age\u00a06, accompanied by\u00a0toe walking\u00a0and a lordotic posture. Prolonged sitting worsens joint contractures, particularly in the hips, knees, elbows, and wrists. [99] Contractures become fixed, contributing to muscular atrophy, skeletal deformities, and the development of progressive scoliosis often associated with pain. [3] [99]", "contents": "Muscular Dystrophy -- History and Physical -- Contractures. Most patients\u00a0with muscular dystrophy experience joint contractures of varying degrees, affecting the elbows, hips, knees, and ankles.\u00a0Arthrogryposis, or joint contractures present at birth, can occur.\u00a0Contractures of the heel cords and iliotibial bands manifest by age\u00a06, accompanied by\u00a0toe walking\u00a0and a lordotic posture. Prolonged sitting worsens joint contractures, particularly in the hips, knees, elbows, and wrists. [99] Contractures become fixed, contributing to muscular atrophy, skeletal deformities, and the development of progressive scoliosis often associated with pain. [3] [99]"}
{"id": "article-25401_60", "title": "Muscular Dystrophy -- History and Physical -- Contractures", "content": "Duchenne muscular dystrophy leads to complications such as muscle weakness, contractures of the knees, hips, and other joints, and scoliosis. [100] The contractures and skeletal deformities that develop from facioscapulohumeral muscular dystrophy are less\u00a0frequent and less prominent than Duchenne muscular dystrophy. [101] Clinical findings like foot drop and depressed or absent muscle stretch reflexes may be present. [102]", "contents": "Muscular Dystrophy -- History and Physical -- Contractures. Duchenne muscular dystrophy leads to complications such as muscle weakness, contractures of the knees, hips, and other joints, and scoliosis. [100] The contractures and skeletal deformities that develop from facioscapulohumeral muscular dystrophy are less\u00a0frequent and less prominent than Duchenne muscular dystrophy. [101] Clinical findings like foot drop and depressed or absent muscle stretch reflexes may be present. [102]"}
{"id": "article-25401_61", "title": "Muscular Dystrophy -- History and Physical -- Delayed motor milestones", "content": "Duchenne muscular dystrophy is usually\u00a0diagnosed in children at\u00a0around the age of 3\u00a0when parents\u00a0observe\u00a0slow motor development. [103] Clinical symptoms\u00a0commonly\u00a0emerge between 5 and 15 years, marked by developmental delays in sitting, standing, and walking. [103] Children affected by Duchenne muscular dystrophy often exhibit clumsiness, frequent falls, and difficulties climbing stairs. [103] In contrast, individuals with Becker muscular dystrophy remain ambulatory into their teens and early 20s, with the average age for wheelchair necessity reported as 25 in one study. [77] The key distinction is that patients with Becker dystrophy can walk beyond age 15,\u00a0while\u00a0those with Duchenne dystrophy typically use a wheelchair by age 12. [103]", "contents": "Muscular Dystrophy -- History and Physical -- Delayed motor milestones. Duchenne muscular dystrophy is usually\u00a0diagnosed in children at\u00a0around the age of 3\u00a0when parents\u00a0observe\u00a0slow motor development. [103] Clinical symptoms\u00a0commonly\u00a0emerge between 5 and 15 years, marked by developmental delays in sitting, standing, and walking. [103] Children affected by Duchenne muscular dystrophy often exhibit clumsiness, frequent falls, and difficulties climbing stairs. [103] In contrast, individuals with Becker muscular dystrophy remain ambulatory into their teens and early 20s, with the average age for wheelchair necessity reported as 25 in one study. [77] The key distinction is that patients with Becker dystrophy can walk beyond age 15,\u00a0while\u00a0those with Duchenne dystrophy typically use a wheelchair by age 12. [103]"}
{"id": "article-25401_62", "title": "Muscular Dystrophy -- History and Physical -- Expressionless facies", "content": "A characteristic feature noted from early childhood is the inability to close the eyes fully. The expression on the face is often described as expressionless, and the weakening of facial muscles results in a \"drooping expression.\"\u00a0In myotonic dystrophy, the face\u00a0takes on a hatchet-shaped appearance due to facial wasting and weakness,\u00a0accompanied\u00a0by bilateral partial ptosis.\u00a0While bilateral facial palsy is rare, it is\u00a0crucial to rule out other possible diagnoses for facial weakness, including upper and lower motor neuron\u00a0disorders,\u00a0through thorough diagnostic tests. [104] Fractures", "contents": "Muscular Dystrophy -- History and Physical -- Expressionless facies. A characteristic feature noted from early childhood is the inability to close the eyes fully. The expression on the face is often described as expressionless, and the weakening of facial muscles results in a \"drooping expression.\"\u00a0In myotonic dystrophy, the face\u00a0takes on a hatchet-shaped appearance due to facial wasting and weakness,\u00a0accompanied\u00a0by bilateral partial ptosis.\u00a0While bilateral facial palsy is rare, it is\u00a0crucial to rule out other possible diagnoses for facial weakness, including upper and lower motor neuron\u00a0disorders,\u00a0through thorough diagnostic tests. [104] Fractures"}
{"id": "article-25401_63", "title": "Muscular Dystrophy -- History and Physical -- Expressionless facies", "content": "Muscle weakness and inactivity, particularly\u00a0in individuals\u00a0using a wheelchair full time,\u00a0contribute to the development of\u00a0osteoporosis and an increased risk of pathologic fractures. Bisphosphonates may\u00a0be considered to enhance bone strength in cases of fractures, although there\u00a0is a lack of\u00a0long-term studies on the safety of bisphosphonates in this population. [105] Gait instability", "contents": "Muscular Dystrophy -- History and Physical -- Expressionless facies. Muscle weakness and inactivity, particularly\u00a0in individuals\u00a0using a wheelchair full time,\u00a0contribute to the development of\u00a0osteoporosis and an increased risk of pathologic fractures. Bisphosphonates may\u00a0be considered to enhance bone strength in cases of fractures, although there\u00a0is a lack of\u00a0long-term studies on the safety of bisphosphonates in this population. [105] Gait instability"}
{"id": "article-25401_64", "title": "Muscular Dystrophy -- History and Physical -- Expressionless facies", "content": "The\u00a0affected individuals, particularly boys, frequently\u00a0stumble and\u00a0struggle\u00a0to keep pace with\u00a0peers\u00a0during play. In\u00a0pediatric disease, parents\u00a0may\u00a0notice\u00a0clumsiness or\u00a0rapid weakness in their child. [106] Activities such as running, jumping, and hopping\u00a0typically demonstrate\u00a0abnormalities. [107]", "contents": "Muscular Dystrophy -- History and Physical -- Expressionless facies. The\u00a0affected individuals, particularly boys, frequently\u00a0stumble and\u00a0struggle\u00a0to keep pace with\u00a0peers\u00a0during play. In\u00a0pediatric disease, parents\u00a0may\u00a0notice\u00a0clumsiness or\u00a0rapid weakness in their child. [106] Activities such as running, jumping, and hopping\u00a0typically demonstrate\u00a0abnormalities. [107]"}
{"id": "article-25401_65", "title": "Muscular Dystrophy -- History and Physical -- Gower sign", "content": "This clinical sign can be\u00a0elicited by\u00a0instructing the child to stand from a sitting position. [108] Children with muscular dystrophy and other\u00a0conditions with muscle wasting\u00a0lack the necessary muscle strength to stand. [108] Instead, they may adopt a prone position, thrust themselves onto all fours, and\u00a0subsequently \"walk\" their hands along their thighs to achieve a standing posture. [109] [108] A Gower sign\u00a0indicates significant proximal muscle weakness, particularly the lumbar and gluteal muscles. [108] Muscle wasting", "contents": "Muscular Dystrophy -- History and Physical -- Gower sign. This clinical sign can be\u00a0elicited by\u00a0instructing the child to stand from a sitting position. [108] Children with muscular dystrophy and other\u00a0conditions with muscle wasting\u00a0lack the necessary muscle strength to stand. [108] Instead, they may adopt a prone position, thrust themselves onto all fours, and\u00a0subsequently \"walk\" their hands along their thighs to achieve a standing posture. [109] [108] A Gower sign\u00a0indicates significant proximal muscle weakness, particularly the lumbar and gluteal muscles. [108] Muscle wasting"}
{"id": "article-25401_66", "title": "Muscular Dystrophy -- History and Physical -- Gower sign", "content": "Muscular weakness\u00a0typically begins in the pelvic girdle, causing a \"waddling\" gait. [103] About 80% of cases exhibit calf muscle hypertrophy. [110] The pattern of muscle wasting\u00a0observed in Becker muscular dystrophy\u00a0closely mirrors\u00a0that of Duchenne disease, with prominent involvement of proximal muscles, particularly\u00a0in the lower extremities.\u00a0As the\u00a0condition\u00a0advances, weakness becomes more widespread. [111] In Duchenne muscular dystrophy, the\u00a0weakening progresses over the following years, resulting in the loss of ambulation\u00a0by 8 to 13.", "contents": "Muscular Dystrophy -- History and Physical -- Gower sign. Muscular weakness\u00a0typically begins in the pelvic girdle, causing a \"waddling\" gait. [103] About 80% of cases exhibit calf muscle hypertrophy. [110] The pattern of muscle wasting\u00a0observed in Becker muscular dystrophy\u00a0closely mirrors\u00a0that of Duchenne disease, with prominent involvement of proximal muscles, particularly\u00a0in the lower extremities.\u00a0As the\u00a0condition\u00a0advances, weakness becomes more widespread. [111] In Duchenne muscular dystrophy, the\u00a0weakening progresses over the following years, resulting in the loss of ambulation\u00a0by 8 to 13."}
{"id": "article-25401_67", "title": "Muscular Dystrophy -- History and Physical -- Myotonia", "content": "Myotonia is a prolonged\u00a0involuntary muscle contraction characterized by a delay in releasing grip during activities such as handshaking or closing the fist. [77] This phenomenon is typically evident around age 5 and can be observed through percussion of the thenar eminence, jaw, and forearm musculature. Forced voluntary closures reveal slow relaxation indicative of myotonia.\u00a0As\u00a0muscle deterioration progresses, the detection of myotonia becomes more challenging. Individuals with myotonic dystrophy may struggle to relax their grip, especially in colder conditions. [105] [112]", "contents": "Muscular Dystrophy -- History and Physical -- Myotonia. Myotonia is a prolonged\u00a0involuntary muscle contraction characterized by a delay in releasing grip during activities such as handshaking or closing the fist. [77] This phenomenon is typically evident around age 5 and can be observed through percussion of the thenar eminence, jaw, and forearm musculature. Forced voluntary closures reveal slow relaxation indicative of myotonia.\u00a0As\u00a0muscle deterioration progresses, the detection of myotonia becomes more challenging. Individuals with myotonic dystrophy may struggle to relax their grip, especially in colder conditions. [105] [112]"}
{"id": "article-25401_68", "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy", "content": "Muscle pseudohypertrophy\u00a0in muscular dystrophy can\u00a0extend to the toes, with boys often presenting in preschool with signs such as muscle weakness, difficulty walking, and visibly enlarged calves. [113] [114] Despite the apparent size increase, the muscle itself is diminished. Calf hypertrophy can also be observed in congenital muscular dystrophy. [115] Proximal muscle weakness", "contents": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy. Muscle pseudohypertrophy\u00a0in muscular dystrophy can\u00a0extend to the toes, with boys often presenting in preschool with signs such as muscle weakness, difficulty walking, and visibly enlarged calves. [113] [114] Despite the apparent size increase, the muscle itself is diminished. Calf hypertrophy can also be observed in congenital muscular dystrophy. [115] Proximal muscle weakness"}
{"id": "article-25401_69", "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy", "content": "Proximal muscle weakness\u00a0is evident, particularly when contrasted with distal weakness in many listed conditions. [116] Specific evaluations, such as rising from a low seat or a squatting posture, are required to assess this aspect. [3]", "contents": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy. Proximal muscle weakness\u00a0is evident, particularly when contrasted with distal weakness in many listed conditions. [116] Specific evaluations, such as rising from a low seat or a squatting posture, are required to assess this aspect. [3]"}
{"id": "article-25401_70", "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy", "content": "In Duchenne muscular dystrophy, muscles of the shoulder girdle are affected in 3 to 5 years, leading to bilateral sternocleidomastoid and trapezius involvement, myalgias without weakness, winging of the scapula, continuous muscle fiber loss resulting in weakness principally of the voluntary muscles of proximal upper and lower extremities. Congenital dystrophy forms may present with hypotonia\u00a0and proximal or generalized muscle weakness.\u00a0Loss of muscle strength is progressive, with more severe leg involvement than arm involvement. By\u00a08\u00a0to 10 years of age, walking may\u00a0necessitate braces. Clinical instability originates in the pelvic girdle,\u00a0causing difficulty in standing from the floor (Gower sign),\u00a0climbing stairs, and a waddling gait\u00a0due to weakness in the lumbar and gluteal muscles. [77]", "contents": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy. In Duchenne muscular dystrophy, muscles of the shoulder girdle are affected in 3 to 5 years, leading to bilateral sternocleidomastoid and trapezius involvement, myalgias without weakness, winging of the scapula, continuous muscle fiber loss resulting in weakness principally of the voluntary muscles of proximal upper and lower extremities. Congenital dystrophy forms may present with hypotonia\u00a0and proximal or generalized muscle weakness.\u00a0Loss of muscle strength is progressive, with more severe leg involvement than arm involvement. By\u00a08\u00a0to 10 years of age, walking may\u00a0necessitate braces. Clinical instability originates in the pelvic girdle,\u00a0causing difficulty in standing from the floor (Gower sign),\u00a0climbing stairs, and a waddling gait\u00a0due to weakness in the lumbar and gluteal muscles. [77]"}
{"id": "article-25401_71", "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy", "content": "Facioscapulohumeral muscular dystrophy begins with weakness and atrophy of facial and shoulder girdle (scapulohumeral) muscles. [117] Limb-girdle muscular dystrophy diagnosis is confirmed by excluding\u00a0acute events causing proximal weakness, and the clinical picture, including genetic pattern, excludes Duchenne and facioscapulohumeral muscular dystrophy. [117]", "contents": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy. Facioscapulohumeral muscular dystrophy begins with weakness and atrophy of facial and shoulder girdle (scapulohumeral) muscles. [117] Limb-girdle muscular dystrophy diagnosis is confirmed by excluding\u00a0acute events causing proximal weakness, and the clinical picture, including genetic pattern, excludes Duchenne and facioscapulohumeral muscular dystrophy. [117]"}
{"id": "article-25401_72", "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy", "content": "Early compromise of neck muscles, including flexors, sternocleidomastoids, and distal limb muscles, is\u00a0observed\u00a0in myotonic dystrophy. [77] Wrist extensors, finger extensors, and intrinsic hand muscle weakness impair function in myotonic dystrophy. [77] Ankle dorsiflexor weakness may induce a foot drop. [77] Proximal muscles, however, continue\u00a0to become more powerful throughout myotonic dystrophy.", "contents": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy. Early compromise of neck muscles, including flexors, sternocleidomastoids, and distal limb muscles, is\u00a0observed\u00a0in myotonic dystrophy. [77] Wrist extensors, finger extensors, and intrinsic hand muscle weakness impair function in myotonic dystrophy. [77] Ankle dorsiflexor weakness may induce a foot drop. [77] Proximal muscles, however, continue\u00a0to become more powerful throughout myotonic dystrophy."}
{"id": "article-25401_73", "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy", "content": "Scapuloperoneal muscular dystrophy, a variant of facioscapulohumeral muscular dystrophy, is different in that distal muscles in the lower extremity are involved early\u00a0rather than the early sign of\u00a0facial and shoulder muscle weakness seen in facioscapulohumeral dystrophy. [77] Scoliosis Once scoliosis begins, it is relentlessly progressive.\u00a0Curves of more than 20\u00b0 require surgical intervention to maintain pulmonary function. [118] Toe walking", "contents": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy. Scapuloperoneal muscular dystrophy, a variant of facioscapulohumeral muscular dystrophy, is different in that distal muscles in the lower extremity are involved early\u00a0rather than the early sign of\u00a0facial and shoulder muscle weakness seen in facioscapulohumeral dystrophy. [77] Scoliosis Once scoliosis begins, it is relentlessly progressive.\u00a0Curves of more than 20\u00b0 require surgical intervention to maintain pulmonary function. [118] Toe walking"}
{"id": "article-25401_74", "title": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy", "content": "The foot assumes an equinovarus position, and the child tends to walk on the toes because of the weakness of the anterior tibial and peroneal muscles. [119] Patients with muscular dystrophy often toe-walk because of the weakness of the anterior tibial and peroneal muscles, causing the feet to assume a talipes equinovarus position. [120]", "contents": "Muscular Dystrophy -- History and Physical -- Pseudohypertrophy. The foot assumes an equinovarus position, and the child tends to walk on the toes because of the weakness of the anterior tibial and peroneal muscles. [119] Patients with muscular dystrophy often toe-walk because of the weakness of the anterior tibial and peroneal muscles, causing the feet to assume a talipes equinovarus position. [120]"}
{"id": "article-25401_75", "title": "Muscular Dystrophy -- History and Physical -- Cognitive dysfunction", "content": "Mild to moderate cognitive\u00a0impairment\u00a0are common but not universal. [121] Intellectual impairment in Duchenne dystrophy is common, with the average intelligence quotient (IQ) approximately\u00a01 standard deviation below the mean. [122] A moderate degree of intellectual disability causes these children to have a mean IQ of approximately 80. [123] Impairment of intellectual function appears nonprogressive, affecting verbal ability more than performance. [124] Mental retardation may occur in Becker dystrophy, but it is not as common as in Duchenne.\u00a0The central nervous system\u00a0is affected by some forms of congenital muscular dystrophy. [121] [125] Seizures and hypersomnia", "contents": "Muscular Dystrophy -- History and Physical -- Cognitive dysfunction. Mild to moderate cognitive\u00a0impairment\u00a0are common but not universal. [121] Intellectual impairment in Duchenne dystrophy is common, with the average intelligence quotient (IQ) approximately\u00a01 standard deviation below the mean. [122] A moderate degree of intellectual disability causes these children to have a mean IQ of approximately 80. [123] Impairment of intellectual function appears nonprogressive, affecting verbal ability more than performance. [124] Mental retardation may occur in Becker dystrophy, but it is not as common as in Duchenne.\u00a0The central nervous system\u00a0is affected by some forms of congenital muscular dystrophy. [121] [125] Seizures and hypersomnia"}
{"id": "article-25401_76", "title": "Muscular Dystrophy -- History and Physical -- Cognitive dysfunction", "content": "The excessive urge to sleep and daytime sleepiness are common. [126] These sleep-related issues in individuals with muscular dystrophy may contribute to overall fatigue and impact daily functioning.\u00a0In merosin and FKRP deficiency associated with muscular dystrophy, the occurrence of mental retardation and seizures is observed in only a minority of patients. [127]", "contents": "Muscular Dystrophy -- History and Physical -- Cognitive dysfunction. The excessive urge to sleep and daytime sleepiness are common. [126] These sleep-related issues in individuals with muscular dystrophy may contribute to overall fatigue and impact daily functioning.\u00a0In merosin and FKRP deficiency associated with muscular dystrophy, the occurrence of mental retardation and seizures is observed in only a minority of patients. [127]"}
{"id": "article-25401_77", "title": "Muscular Dystrophy -- History and Physical -- Visual disturbances", "content": "Myotonic dystrophy may manifest as ptosis, resulting in impaired vision and contributing to the characteristic clinical presentation of the condition. [128] [129] Moreover, individuals with myotonic dystrophy may experience double vision (diplopia) and other visual disturbances due to the involvement of eye muscles, further impacting their ocular function.", "contents": "Muscular Dystrophy -- History and Physical -- Visual disturbances. Myotonic dystrophy may manifest as ptosis, resulting in impaired vision and contributing to the characteristic clinical presentation of the condition. [128] [129] Moreover, individuals with myotonic dystrophy may experience double vision (diplopia) and other visual disturbances due to the involvement of eye muscles, further impacting their ocular function."}
{"id": "article-25401_78", "title": "Muscular Dystrophy -- History and Physical -- Respiratory Findings", "content": "Chest deformity", "contents": "Muscular Dystrophy -- History and Physical -- Respiratory Findings. Chest deformity"}
{"id": "article-25401_79", "title": "Muscular Dystrophy -- History and Physical -- Respiratory Findings", "content": "The presence of scoliosis-related chest deformity further compromises pulmonary function, exacerbating\u00a0the respiratory challenges already imposed by\u00a0muscle weakness in individuals with myotonic dystrophy. [130] Additionally, it is essential to conduct examinations for gynecomastia,\u00a0as this condition can coexist in patients with\u00a0myotonic dystrophy. Recurrent pulmonary infections", "contents": "Muscular Dystrophy -- History and Physical -- Respiratory Findings. The presence of scoliosis-related chest deformity further compromises pulmonary function, exacerbating\u00a0the respiratory challenges already imposed by\u00a0muscle weakness in individuals with myotonic dystrophy. [130] Additionally, it is essential to conduct examinations for gynecomastia,\u00a0as this condition can coexist in patients with\u00a0myotonic dystrophy. Recurrent pulmonary infections"}
{"id": "article-25401_80", "title": "Muscular Dystrophy -- History and Physical -- Respiratory Findings", "content": "Around the age of 16\u00a0to 18,\u00a0individuals affected by muscular dystrophy become increasingly vulnerable to severe and potentially fatal\u00a0pulmonary infections. [131] The heightened susceptibility to respiratory tract infections, coupled with the progressive deterioration of pulmonary function, typically results in premature mortality,\u00a0often occurring in the 20s. [132] Respiratory insufficiency", "contents": "Muscular Dystrophy -- History and Physical -- Respiratory Findings. Around the age of 16\u00a0to 18,\u00a0individuals affected by muscular dystrophy become increasingly vulnerable to severe and potentially fatal\u00a0pulmonary infections. [131] The heightened susceptibility to respiratory tract infections, coupled with the progressive deterioration of pulmonary function, typically results in premature mortality,\u00a0often occurring in the 20s. [132] Respiratory insufficiency"}
{"id": "article-25401_81", "title": "Muscular Dystrophy -- History and Physical -- Respiratory Findings", "content": "Respiratory failure is the most common cause of death in individuals with muscular dystrophy. [82] Careful inspection reveals areas of muscle wasting.\u00a0An urgent comprehensive assessment is crucial for patients exhibiting sudden-onset muscle weakness, as respiratory muscle involvement\u00a0can progress\u00a0to respiratory failure. [133] Diaphragm and intercostal muscle weakness may contribute to respiratory insufficiency in some cases. [39]", "contents": "Muscular Dystrophy -- History and Physical -- Respiratory Findings. Respiratory failure is the most common cause of death in individuals with muscular dystrophy. [82] Careful inspection reveals areas of muscle wasting.\u00a0An urgent comprehensive assessment is crucial for patients exhibiting sudden-onset muscle weakness, as respiratory muscle involvement\u00a0can progress\u00a0to respiratory failure. [133] Diaphragm and intercostal muscle weakness may contribute to respiratory insufficiency in some cases. [39]"}
{"id": "article-25401_82", "title": "Muscular Dystrophy -- History and Physical -- Respiratory Findings", "content": "The disease often follows a progressive course\u00a0with subsequent\u00a0respiratory complications potentially culminating in respiratory failure.\u00a0The development of\u00a0marked kyphoscoliosis further compromises pulmonary function, especially as children transition to wheelchair use. With advancing age, escalating muscle weakness and\u00a0respiratory involvement result in\u00a0breathing difficulties, particularly\u00a0during sleeping. [134]", "contents": "Muscular Dystrophy -- History and Physical -- Respiratory Findings. The disease often follows a progressive course\u00a0with subsequent\u00a0respiratory complications potentially culminating in respiratory failure.\u00a0The development of\u00a0marked kyphoscoliosis further compromises pulmonary function, especially as children transition to wheelchair use. With advancing age, escalating muscle weakness and\u00a0respiratory involvement result in\u00a0breathing difficulties, particularly\u00a0during sleeping. [134]"}
{"id": "article-25401_83", "title": "Muscular Dystrophy -- History and Physical -- Sleep apnea", "content": "Individuals with muscular dystrophy commonly experience an increased need or desire for sleep, often accompanied by diminished motivation. [135] Continuous monitoring and appropriate interventions are crucial to manage sleep apnea in this population and improve overall respiratory health.", "contents": "Muscular Dystrophy -- History and Physical -- Sleep apnea. Individuals with muscular dystrophy commonly experience an increased need or desire for sleep, often accompanied by diminished motivation. [135] Continuous monitoring and appropriate interventions are crucial to manage sleep apnea in this population and improve overall respiratory health."}
{"id": "article-25401_84", "title": "Muscular Dystrophy -- History and Physical -- Other Findings", "content": "Individuals with certain forms of muscular dystrophy may experience challenges with bladder control, leading to symptoms such as urinary urgency. [136] Moreover, an eye exam may\u00a0reveal iridescent spots, potentially indicating an underlying dystrophy. [137] [138] Esophageal muscles can also be involved, causing dysphagia. [75]", "contents": "Muscular Dystrophy -- History and Physical -- Other Findings. Individuals with certain forms of muscular dystrophy may experience challenges with bladder control, leading to symptoms such as urinary urgency. [136] Moreover, an eye exam may\u00a0reveal iridescent spots, potentially indicating an underlying dystrophy. [137] [138] Esophageal muscles can also be involved, causing dysphagia. [75]"}
{"id": "article-25401_85", "title": "Muscular Dystrophy -- History and Physical -- Other Findings", "content": "Gonadal atrophy is associated with myotonic dystrophy. [47] [139] Upon physical examination, small soft testes may be noted, as well as hair loss. [47] Older individuals may have concerns of impotence likely caused by gonadal atrophy. [140] Generalized digestive complaints", "contents": "Muscular Dystrophy -- History and Physical -- Other Findings. Gonadal atrophy is associated with myotonic dystrophy. [47] [139] Upon physical examination, small soft testes may be noted, as well as hair loss. [47] Older individuals may have concerns of impotence likely caused by gonadal atrophy. [140] Generalized digestive complaints"}
{"id": "article-25401_86", "title": "Muscular Dystrophy -- History and Physical -- Other Findings", "content": "Smooth muscle dysfunction associated with certain forms of muscular dystrophy may contribute to conditions such as megacolon, volvulus, cramping pain, and malabsorption in the gastrointestinal tract. [141] This dysfunction manifests as disturbed gastrointestinal peristalsis, decreasing esophageal and colonic motility. [142] Commonly, bowel functions are often mildly affected, presenting with constipation as a frequent symptom. [143] Severe complications, such as aspiration of food\u00a0and acute gastric dilation, may contribute to causes of death. Furthermore, palatal, pharyngeal, and tongue involvement can result in\u00a0dysarthric speech, nasal voice, and swallowing problems. [144] [145] Insulin resistance", "contents": "Muscular Dystrophy -- History and Physical -- Other Findings. Smooth muscle dysfunction associated with certain forms of muscular dystrophy may contribute to conditions such as megacolon, volvulus, cramping pain, and malabsorption in the gastrointestinal tract. [141] This dysfunction manifests as disturbed gastrointestinal peristalsis, decreasing esophageal and colonic motility. [142] Commonly, bowel functions are often mildly affected, presenting with constipation as a frequent symptom. [143] Severe complications, such as aspiration of food\u00a0and acute gastric dilation, may contribute to causes of death. Furthermore, palatal, pharyngeal, and tongue involvement can result in\u00a0dysarthric speech, nasal voice, and swallowing problems. [144] [145] Insulin resistance"}
{"id": "article-25401_87", "title": "Muscular Dystrophy -- History and Physical -- Other Findings", "content": "Individuals with muscular dystrophy may encounter challenges related to glucose metabolism, contributing to the increased prevalence of diabetes in this population. [146] This association underscores the importance of regularly monitoring and managing glucose levels in individuals with muscular dystrophy to address potential complications and optimize overall health.", "contents": "Muscular Dystrophy -- History and Physical -- Other Findings. Individuals with muscular dystrophy may encounter challenges related to glucose metabolism, contributing to the increased prevalence of diabetes in this population. [146] This association underscores the importance of regularly monitoring and managing glucose levels in individuals with muscular dystrophy to address potential complications and optimize overall health."}
{"id": "article-25401_88", "title": "Muscular Dystrophy -- Evaluation", "content": "The choice of specific tests\u00a0depends\u00a0on the patient's symptoms, medical history, and suspected muscular dystrophy type. A comprehensive approach involving a combination of tests is often required to establish a definitive diagnosis and formulate an effective treatment strategy.", "contents": "Muscular Dystrophy -- Evaluation. The choice of specific tests\u00a0depends\u00a0on the patient's symptoms, medical history, and suspected muscular dystrophy type. A comprehensive approach involving a combination of tests is often required to establish a definitive diagnosis and formulate an effective treatment strategy."}
{"id": "article-25401_89", "title": "Muscular Dystrophy -- Evaluation -- Laboratory Tests", "content": "Liver Enzymes Alanine transaminase (ALT),\u00a0Aspartate aminotransferase (AST) Elevated levels are observed in muscular dystrophy. [79] Aldolase:  Elevated levels are observed in muscular dystrophy, with a subsequent decrease in later stages. [147] Arterial blood gases: Respiratory acidosis can develop in the presence of defects in muscles involved in respiration, which can occur in muscular dystrophy. [148] Creatine\u00a0phosphokinase Creatinine phosphokinase or creatinine kinase (CK, CPK) and creatine kinase isoenzymes (CK-MB\u00a0and CK-MM) Elevated levels\u00a0are observed in muscular dystrophy. [149]", "contents": "Muscular Dystrophy -- Evaluation -- Laboratory Tests. Liver Enzymes Alanine transaminase (ALT),\u00a0Aspartate aminotransferase (AST) Elevated levels are observed in muscular dystrophy. [79] Aldolase:  Elevated levels are observed in muscular dystrophy, with a subsequent decrease in later stages. [147] Arterial blood gases: Respiratory acidosis can develop in the presence of defects in muscles involved in respiration, which can occur in muscular dystrophy. [148] Creatine\u00a0phosphokinase Creatinine phosphokinase or creatinine kinase (CK, CPK) and creatine kinase isoenzymes (CK-MB\u00a0and CK-MM) Elevated levels\u00a0are observed in muscular dystrophy. [149]"}
{"id": "article-25401_90", "title": "Muscular Dystrophy -- Evaluation -- Laboratory Tests", "content": "The serum enzymes, especially CPK, are increased to more than\u00a010 times normal, even in infancy and before the onset of weakness. [150] Diagnosis is suggested (a high\u00a0CPK level does not confirm the diagnosis because many other alterations can also increase CPK) by measuring the blood CPK level, which can be 100 times the normal level, with diagnostic confirmation by genetic testing for mutations in the dystrophin gene. [151] Serum CPK levels are invariably elevated between 20 and 100 times normal in Duchenne muscular dystrophy. [152] The levels are abnormal at birth, but values decline late in the disease because of inactivity and loss of muscle mass. [153] Elevated CPK levels at birth are diagnostic indicators of Duchenne muscular dystrophy. [154] Identifying female carriers of the\u00a0condition is not achievable with certainty, but serum CPK is elevated in 60% to 80% of carriers. [155] Serum CPK can be 2 to 20 times above normal in Emery-Dreifuss muscular dystrophy. [156]", "contents": "Muscular Dystrophy -- Evaluation -- Laboratory Tests. The serum enzymes, especially CPK, are increased to more than\u00a010 times normal, even in infancy and before the onset of weakness. [150] Diagnosis is suggested (a high\u00a0CPK level does not confirm the diagnosis because many other alterations can also increase CPK) by measuring the blood CPK level, which can be 100 times the normal level, with diagnostic confirmation by genetic testing for mutations in the dystrophin gene. [151] Serum CPK levels are invariably elevated between 20 and 100 times normal in Duchenne muscular dystrophy. [152] The levels are abnormal at birth, but values decline late in the disease because of inactivity and loss of muscle mass. [153] Elevated CPK levels at birth are diagnostic indicators of Duchenne muscular dystrophy. [154] Identifying female carriers of the\u00a0condition is not achievable with certainty, but serum CPK is elevated in 60% to 80% of carriers. [155] Serum CPK can be 2 to 20 times above normal in Emery-Dreifuss muscular dystrophy. [156]"}
{"id": "article-25401_91", "title": "Muscular Dystrophy -- Evaluation -- Laboratory Tests", "content": "Myotonic dystrophy may be associated with a normal CPK or only mild elevation. [84] Lactate dehydrogenase:  Elevated in muscular dystrophy. [147]", "contents": "Muscular Dystrophy -- Evaluation -- Laboratory Tests. Myotonic dystrophy may be associated with a normal CPK or only mild elevation. [84] Lactate dehydrogenase:  Elevated in muscular dystrophy. [147]"}
{"id": "article-25401_92", "title": "Muscular Dystrophy -- Evaluation -- Laboratory Tests", "content": "Urinalysis:  Findings in individuals with muscular dystrophy often reveal the presence of glucose in the urine, which can be attributed to the elevated prevalence of diabetes mellitus within this population. [157] Myoglobinuria may also\u00a0be detected. [147]", "contents": "Muscular Dystrophy -- Evaluation -- Laboratory Tests. Urinalysis:  Findings in individuals with muscular dystrophy often reveal the presence of glucose in the urine, which can be attributed to the elevated prevalence of diabetes mellitus within this population. [157] Myoglobinuria may also\u00a0be detected. [147]"}
{"id": "article-25401_93", "title": "Muscular Dystrophy -- Evaluation -- Radiographic Tests", "content": "Magnetic resonance imaging: Coronal T1 weighted magnetic resonance imaging (MRI)\u00a0is a valuable diagnostic tool to confirm the\u00a0nonuniform fatty atrophy associated with muscular dystrophy. [158] A\u00a0relatively normal sartorius can be observed. Lateral radiographs may\u00a0reveal a cavus foot deformity and diffuse osteopenia. [159] The sagittal view\u00a0can show diffuse fat replacement of the gastrocnemius & semimembranosus muscles. These structural changes contribute to the\u00a0characteristic prominence of calves\u00a0often observed\u00a0in affected children. [114]", "contents": "Muscular Dystrophy -- Evaluation -- Radiographic Tests. Magnetic resonance imaging: Coronal T1 weighted magnetic resonance imaging (MRI)\u00a0is a valuable diagnostic tool to confirm the\u00a0nonuniform fatty atrophy associated with muscular dystrophy. [158] A\u00a0relatively normal sartorius can be observed. Lateral radiographs may\u00a0reveal a cavus foot deformity and diffuse osteopenia. [159] The sagittal view\u00a0can show diffuse fat replacement of the gastrocnemius & semimembranosus muscles. These structural changes contribute to the\u00a0characteristic prominence of calves\u00a0often observed\u00a0in affected children. [114]"}
{"id": "article-25401_94", "title": "Muscular Dystrophy -- Evaluation -- Radiographic Tests", "content": "Computerized tomography:\u00a0Axial computerized tomography (CT)\u00a0reveals denervation hypertrophy of the tensor fascia lata. This muscle\u00a0exhibits enlargement accompanied by an increase in intramuscular fat. [160]", "contents": "Muscular Dystrophy -- Evaluation -- Radiographic Tests. Computerized tomography:\u00a0Axial computerized tomography (CT)\u00a0reveals denervation hypertrophy of the tensor fascia lata. This muscle\u00a0exhibits enlargement accompanied by an increase in intramuscular fat. [160]"}
{"id": "article-25401_95", "title": "Muscular Dystrophy -- Evaluation -- Other Tests", "content": "Chromosomal analysis: The DNA deletion size does not predict clinical severity in Becker and Duchenne dystrophies. [161] In approximately 95% of Becker dystrophy cases, \"in-frame\" mutations, despite the DNA deletion, maintain the translational read frame of messenger RNA.\u00a0This preservation enables the development of dystrophin, as evident in the presence of dystrophin on Western blot examination. [162] Electrocardiogram: Often, patients will have annual electrocardiograms (ECGs) as a proactive measure to monitor the potential development of cardiomyopathy. This diagnostic study reveals atrial and atrioventricular rhythm disturbances. The typical\u00a0ECG findings\u00a0include an increased net RS in lead V1, deep, narrow Q waves in the precordial leads, and\u00a0A\u00a0QRS complex\u00a0too narrow to be right bundle branch block; and tall right precordial R waves in V1. [163] [164] The dominant R wave in lead V1\u00a0is a crucial\u00a0clue\u00a0for\u00a0an\u00a0accurate\u00a0diagnosis. [165]", "contents": "Muscular Dystrophy -- Evaluation -- Other Tests. Chromosomal analysis: The DNA deletion size does not predict clinical severity in Becker and Duchenne dystrophies. [161] In approximately 95% of Becker dystrophy cases, \"in-frame\" mutations, despite the DNA deletion, maintain the translational read frame of messenger RNA.\u00a0This preservation enables the development of dystrophin, as evident in the presence of dystrophin on Western blot examination. [162] Electrocardiogram: Often, patients will have annual electrocardiograms (ECGs) as a proactive measure to monitor the potential development of cardiomyopathy. This diagnostic study reveals atrial and atrioventricular rhythm disturbances. The typical\u00a0ECG findings\u00a0include an increased net RS in lead V1, deep, narrow Q waves in the precordial leads, and\u00a0A\u00a0QRS complex\u00a0too narrow to be right bundle branch block; and tall right precordial R waves in V1. [163] [164] The dominant R wave in lead V1\u00a0is a crucial\u00a0clue\u00a0for\u00a0an\u00a0accurate\u00a0diagnosis. [165]"}
{"id": "article-25401_96", "title": "Muscular Dystrophy -- Evaluation -- Other Tests", "content": "There are abnormal Q waves in the precordial leads.\u00a0Prominent Q waves in lead II. [166] QRS axis shows deviation. [167] Significant ECG irregularities and the diagnosis of atrial tachyarrhythmia are\u00a0indicative of the risk of sudden death. [168] A P wave with a\u00a0prominent early deflection in lead V1\u00a0reflects right atrial enlargement. [166] The ECG could mimic pulmonary hypertension, primarily observed in lead V1 with\u00a0QRS right axis deviation. [166] While less likely, an old true posterior wall myocardial infarction could be considered. However, looking for an associated inferior wall myocardial infarction, which will be absent\u00a0in cases associated with dystrophinopathies, is essential. [90] A progressively lengthening PR interval and QRS duration indicate the increasing severity of conduction disease. [169] An implantable cardioverter-defibrillator should be considered\u00a0for all patients. [86] Electromyography:", "contents": "Muscular Dystrophy -- Evaluation -- Other Tests. There are abnormal Q waves in the precordial leads.\u00a0Prominent Q waves in lead II. [166] QRS axis shows deviation. [167] Significant ECG irregularities and the diagnosis of atrial tachyarrhythmia are\u00a0indicative of the risk of sudden death. [168] A P wave with a\u00a0prominent early deflection in lead V1\u00a0reflects right atrial enlargement. [166] The ECG could mimic pulmonary hypertension, primarily observed in lead V1 with\u00a0QRS right axis deviation. [166] While less likely, an old true posterior wall myocardial infarction could be considered. However, looking for an associated inferior wall myocardial infarction, which will be absent\u00a0in cases associated with dystrophinopathies, is essential. [90] A progressively lengthening PR interval and QRS duration indicate the increasing severity of conduction disease. [169] An implantable cardioverter-defibrillator should be considered\u00a0for all patients. [86] Electromyography:"}
{"id": "article-25401_97", "title": "Muscular Dystrophy -- Evaluation -- Other Tests", "content": "Electromyography (EMG) reveals characteristic features of myopathy during the assessment. Enables evaluation\u00a0of muscle denervation, myopathies, myotonic dystrophy, and motor neuron disease. EMG demonstrates features typical of myopathy. [170] In clinical examination and EMG, changes are\u00a0detectable in nearly any muscle, marked by the waxing and waning of potentials termed the \"dive bomber effect.\" [171] Genetic testing: A definitive diagnosis of muscular dystrophy can be established\u00a0through mutation analysis performed on peripheral blood leukocytes. [172] Genetic testing\u00a0reveals deletions or duplications of the dystrophin gene in 65% of patients with Becker dystrophy,\u00a0a proportion similar to\u00a0Duchenne dystrophy. [173] Multiplex polymerase chain reaction (PCR) is commonly employed to detect deletions, while sequencing is utilized to identify other mutations. [174]", "contents": "Muscular Dystrophy -- Evaluation -- Other Tests. Electromyography (EMG) reveals characteristic features of myopathy during the assessment. Enables evaluation\u00a0of muscle denervation, myopathies, myotonic dystrophy, and motor neuron disease. EMG demonstrates features typical of myopathy. [170] In clinical examination and EMG, changes are\u00a0detectable in nearly any muscle, marked by the waxing and waning of potentials termed the \"dive bomber effect.\" [171] Genetic testing: A definitive diagnosis of muscular dystrophy can be established\u00a0through mutation analysis performed on peripheral blood leukocytes. [172] Genetic testing\u00a0reveals deletions or duplications of the dystrophin gene in 65% of patients with Becker dystrophy,\u00a0a proportion similar to\u00a0Duchenne dystrophy. [173] Multiplex polymerase chain reaction (PCR) is commonly employed to detect deletions, while sequencing is utilized to identify other mutations. [174]"}
{"id": "article-25401_98", "title": "Muscular Dystrophy -- Evaluation -- Other Tests", "content": "Carrier females\u00a0can be determined\u00a0through mutation testing or by linkage to intragenic markers, allowing for an intragenic recombination rate of 12%. [175]", "contents": "Muscular Dystrophy -- Evaluation -- Other Tests. Carrier females\u00a0can be determined\u00a0through mutation testing or by linkage to intragenic markers, allowing for an intragenic recombination rate of 12%. [175]"}
{"id": "article-25401_99", "title": "Muscular Dystrophy -- Evaluation -- Immunocytochemistry:", "content": "A definitive diagnosis of muscular dystrophy\u00a0relies on identifying\u00a0dystrophin deficiency in a muscle tissue biopsy. [176] Staining muscle with dystrophin antibodies can demonstrate the absence or deficiency of dystrophin localizing to the sarcolemmal membrane. [1] Disease carriers\u00a0exhibit\u00a0a mosaic pattern, but dystrophin analysis\u00a0in muscle biopsy specimens\u00a0is not a reliable method for carrier detection. [177] Immunohistochemistry\u00a0also reveals\u00a0the absence of emerin staining of myonuclei in X-linked Emery-Dreifuss due to emerin mutations. [178] Muscle biopsy The muscle biopsy\u00a0reveals varying muscle fiber sizes and small groups of necrotic and regenerating fibers. Lost muscle fibers are replaced by connective tissue and fat. Muscle biopsy usually shows nonspecific dystrophic features, although cases associated with FHL1 mutations have features of myofibrillar myopathy. [179] In 50% of cases, muscle biopsy shows muscle atrophy\u00a0selectively involving Type 1 fibers. [75]", "contents": "Muscular Dystrophy -- Evaluation -- Immunocytochemistry:. A definitive diagnosis of muscular dystrophy\u00a0relies on identifying\u00a0dystrophin deficiency in a muscle tissue biopsy. [176] Staining muscle with dystrophin antibodies can demonstrate the absence or deficiency of dystrophin localizing to the sarcolemmal membrane. [1] Disease carriers\u00a0exhibit\u00a0a mosaic pattern, but dystrophin analysis\u00a0in muscle biopsy specimens\u00a0is not a reliable method for carrier detection. [177] Immunohistochemistry\u00a0also reveals\u00a0the absence of emerin staining of myonuclei in X-linked Emery-Dreifuss due to emerin mutations. [178] Muscle biopsy The muscle biopsy\u00a0reveals varying muscle fiber sizes and small groups of necrotic and regenerating fibers. Lost muscle fibers are replaced by connective tissue and fat. Muscle biopsy usually shows nonspecific dystrophic features, although cases associated with FHL1 mutations have features of myofibrillar myopathy. [179] In 50% of cases, muscle biopsy shows muscle atrophy\u00a0selectively involving Type 1 fibers. [75]"}
{"id": "article-25401_100", "title": "Muscular Dystrophy -- Evaluation", "content": "Various agentic nuclei can be observed in muscle cells as well as in dysplastic fibers with intracytoplasmic nuclear clusters. [180] Histologic changes in muscle include degeneration of muscle fibers,\u00a0featuring variation in fiber size and the presence of central nuclei. [181] In scapuloperoneal muscular dystrophy, fiber splitting is observed, and fibers appear profusely \"moth-eaten\" and whorled. [182]", "contents": "Muscular Dystrophy -- Evaluation. Various agentic nuclei can be observed in muscle cells as well as in dysplastic fibers with intracytoplasmic nuclear clusters. [180] Histologic changes in muscle include degeneration of muscle fibers,\u00a0featuring variation in fiber size and the presence of central nuclei. [181] In scapuloperoneal muscular dystrophy, fiber splitting is observed, and fibers appear profusely \"moth-eaten\" and whorled. [182]"}
{"id": "article-25401_101", "title": "Muscular Dystrophy -- Evaluation", "content": "Polysomnogram: Excessive daytime sleepiness with or without sleep apnea is common. Sleep studies, noninvasive respiratory support (biphasic positive airway pressure [BiPAP]), and treatment with modafinil may be beneficial. [183] Pulmonary function tests: Assessing lung function with a pulmonary function test (PFT) is valuable in evaluating the impact of muscular dystrophy on respiratory capabilities. Slit Lamp:\u00a0An examination for cataracts that may be present in patients with muscular dystrophy. [184]", "contents": "Muscular Dystrophy -- Evaluation. Polysomnogram: Excessive daytime sleepiness with or without sleep apnea is common. Sleep studies, noninvasive respiratory support (biphasic positive airway pressure [BiPAP]), and treatment with modafinil may be beneficial. [183] Pulmonary function tests: Assessing lung function with a pulmonary function test (PFT) is valuable in evaluating the impact of muscular dystrophy on respiratory capabilities. Slit Lamp:\u00a0An examination for cataracts that may be present in patients with muscular dystrophy. [184]"}
{"id": "article-25401_102", "title": "Muscular Dystrophy -- Evaluation", "content": "Western blot:\u00a0Duchenne dystrophy can\u00a0be diagnosed through\u00a0Western blot analysis of muscle biopsy specimens, revealing abnormalities in dystrophin proteins' quantity and molecular weight. In Becker muscular dystrophy, dystrophin levels\u00a0may appear normal on Western blot despite the abnormal protein, contrasting with significantly decreased dystrophin levels in individuals with Duchenne muscular dystrophy. [185]", "contents": "Muscular Dystrophy -- Evaluation. Western blot:\u00a0Duchenne dystrophy can\u00a0be diagnosed through\u00a0Western blot analysis of muscle biopsy specimens, revealing abnormalities in dystrophin proteins' quantity and molecular weight. In Becker muscular dystrophy, dystrophin levels\u00a0may appear normal on Western blot despite the abnormal protein, contrasting with significantly decreased dystrophin levels in individuals with Duchenne muscular dystrophy. [185]"}
{"id": "article-25401_103", "title": "Muscular Dystrophy -- Treatment / Management", "content": "Treatment for muscular dystrophy focuses on managing symptoms, slowing the progression of the disease, and improving the quality of life for affected individuals. While there is no cure for muscular dystrophy, various interventions aim to address specific challenges associated with muscle weakness, mobility issues, and potential complications. Physical therapy, assistive devices, medications, and, in some cases, surgical procedures may be part of a comprehensive treatment plan.", "contents": "Muscular Dystrophy -- Treatment / Management. Treatment for muscular dystrophy focuses on managing symptoms, slowing the progression of the disease, and improving the quality of life for affected individuals. While there is no cure for muscular dystrophy, various interventions aim to address specific challenges associated with muscle weakness, mobility issues, and potential complications. Physical therapy, assistive devices, medications, and, in some cases, surgical procedures may be part of a comprehensive treatment plan."}
{"id": "article-25401_104", "title": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions", "content": "Antiarrhythmics play a pivotal role in managing cardiac complications associated with muscular dystrophy. For patients experiencing prevalent cardiac conduction issues, the use of angiotensin-converting enzyme (ACE) inhibitors and specific antiarrhythmic drugs is a common approach. In cases of atrial arrhythmias, preference is given to medications like flecainide, propafenone, and beta-blockers. Amiodarone is reserved for patients unresponsive to initial drugs, taking into account factors such as the patient's age, the need for long-term therapy, and the heightened risk of adverse effects on the thyroid and pulmonary function. [186]", "contents": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions. Antiarrhythmics play a pivotal role in managing cardiac complications associated with muscular dystrophy. For patients experiencing prevalent cardiac conduction issues, the use of angiotensin-converting enzyme (ACE) inhibitors and specific antiarrhythmic drugs is a common approach. In cases of atrial arrhythmias, preference is given to medications like flecainide, propafenone, and beta-blockers. Amiodarone is reserved for patients unresponsive to initial drugs, taking into account factors such as the patient's age, the need for long-term therapy, and the heightened risk of adverse effects on the thyroid and pulmonary function. [186]"}
{"id": "article-25401_105", "title": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions", "content": "Myotonia, characterized by muscle rigidity and associated pain, can be effectively managed with sodium channel blockers such as phenytoin, procainamide, or mexiletine. Dosing for these medications is as follows: Phenytoin 100 mg orally 3 times daily Procainamide 0.5 to 1 g orally 4 times daily Mexiletine 150 to 200 mg orally 3 times daily", "contents": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions. Myotonia, characterized by muscle rigidity and associated pain, can be effectively managed with sodium channel blockers such as phenytoin, procainamide, or mexiletine. Dosing for these medications is as follows: Phenytoin 100 mg orally 3 times daily Procainamide 0.5 to 1 g orally 4 times daily Mexiletine 150 to 200 mg orally 3 times daily"}
{"id": "article-25401_106", "title": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions", "content": "However, the associated side effects, particularly for antiarrhythmic medications, are often limiting. [187] Phenytoin and mexiletine are preferred for symptomatic patients requiring anti-myotonia medication, as other medications like quinine and procainamide may elevate the risk of cardiovascular complications. [188]", "contents": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions. However, the associated side effects, particularly for antiarrhythmic medications, are often limiting. [187] Phenytoin and mexiletine are preferred for symptomatic patients requiring anti-myotonia medication, as other medications like quinine and procainamide may elevate the risk of cardiovascular complications. [188]"}
{"id": "article-25401_107", "title": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions", "content": "Steroids, specifically glucocorticoids like prednisone, administered at a dose of 0.75 mg/kg per day, significantly slow the progression of muscular dystrophy for up to\u00a03 years. [189] While some patients may not tolerate glucocorticoid therapy due to factors like weight gain and an increased risk of fractures, recent evidence suggests that early oral steroid use can lead to markedly improved outcomes. [190] [191] This includes additional walking years for children and increased life expectancy. [71] The use of glucocorticoids in Becker dystrophy and their effectiveness in treating myotonic muscular dystrophy remain areas where research is ongoing, and evidence is not yet conclusive. [192] [193] Some individuals with facioscapulohumeral muscular dystrophy improve with steroid therapy, particularly when rapidly progressive weakness is observed. [194]", "contents": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions. Steroids, specifically glucocorticoids like prednisone, administered at a dose of 0.75 mg/kg per day, significantly slow the progression of muscular dystrophy for up to\u00a03 years. [189] While some patients may not tolerate glucocorticoid therapy due to factors like weight gain and an increased risk of fractures, recent evidence suggests that early oral steroid use can lead to markedly improved outcomes. [190] [191] This includes additional walking years for children and increased life expectancy. [71] The use of glucocorticoids in Becker dystrophy and their effectiveness in treating myotonic muscular dystrophy remain areas where research is ongoing, and evidence is not yet conclusive. [192] [193] Some individuals with facioscapulohumeral muscular dystrophy improve with steroid therapy, particularly when rapidly progressive weakness is observed. [194]"}
{"id": "article-25401_108", "title": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions", "content": "Medications like antiepileptics and nonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in treating symptoms due to muscular dystrophy.\u00a0Antiepileptics play a crucial role in effectively managing seizures in some individuals with muscular dystrophy. [195] The use of NSAIDs is part of the treatment plan to reduce pain and inflammation. [196]", "contents": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions. Medications like antiepileptics and nonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in treating symptoms due to muscular dystrophy.\u00a0Antiepileptics play a crucial role in effectively managing seizures in some individuals with muscular dystrophy. [195] The use of NSAIDs is part of the treatment plan to reduce pain and inflammation. [196]"}
{"id": "article-25401_109", "title": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions", "content": "Golodirsen\u00a0(SRP-4053),\u00a0an antisense therapy\u00a0designed to treat Duchenne muscular dystrophy, is approved by the Food and Drug Administration (FDA). However, the evidence supporting its use, particularly in cases requiring exon 53 skipping, is still evolving and not fully established. [197] [198]", "contents": "Muscular Dystrophy -- Treatment / Management -- Pharmaceutical\u00a0Interventions. Golodirsen\u00a0(SRP-4053),\u00a0an antisense therapy\u00a0designed to treat Duchenne muscular dystrophy, is approved by the Food and Drug Administration (FDA). However, the evidence supporting its use, particularly in cases requiring exon 53 skipping, is still evolving and not fully established. [197] [198]"}
{"id": "article-25401_110", "title": "Muscular Dystrophy -- Treatment / Management -- Surgical Interventions", "content": "Various surgical interventions play a crucial role in managing muscular dystrophy, each tailored to address specific aspects of the condition. Contracture release, achieved through surgical means, is employed to maintain normal function for as long as possible. [199] Adjunct therapies like massage and heat treatments can complement this procedure.", "contents": "Muscular Dystrophy -- Treatment / Management -- Surgical Interventions. Various surgical interventions play a crucial role in managing muscular dystrophy, each tailored to address specific aspects of the condition. Contracture release, achieved through surgical means, is employed to maintain normal function for as long as possible. [199] Adjunct therapies like massage and heat treatments can complement this procedure."}
{"id": "article-25401_111", "title": "Muscular Dystrophy -- Treatment / Management -- Surgical Interventions", "content": "In cases where cardiac complications are evident, installing a defibrillator or cardiac pacemaker may be considered to monitor and manage cardiomyopathy and arrhythmias, potentially offering life-saving benefits. [86] Indications for cardiac pacemaker placement are as follows: [200] [201] Severe syncope Established conduction system disorders with a second-degree heart block Tri-fascicular conduction abnormalities with PR interval lengthening Advanced cardiac block", "contents": "Muscular Dystrophy -- Treatment / Management -- Surgical Interventions. In cases where cardiac complications are evident, installing a defibrillator or cardiac pacemaker may be considered to monitor and manage cardiomyopathy and arrhythmias, potentially offering life-saving benefits. [86] Indications for cardiac pacemaker placement are as follows: [200] [201] Severe syncope Established conduction system disorders with a second-degree heart block Tri-fascicular conduction abnormalities with PR interval lengthening Advanced cardiac block"}
{"id": "article-25401_112", "title": "Muscular Dystrophy -- Treatment / Management -- Surgical Interventions", "content": "For individuals with facioscapulohumeral muscular dystrophy, shoulder surgery might be beneficial to stabilize the shoulder. [202] When scoliotic curves exceed 20\u00b0, spinal correction through surgery can prolong respiratory function, walking ability, or both. [118]", "contents": "Muscular Dystrophy -- Treatment / Management -- Surgical Interventions. For individuals with facioscapulohumeral muscular dystrophy, shoulder surgery might be beneficial to stabilize the shoulder. [202] When scoliotic curves exceed 20\u00b0, spinal correction through surgery can prolong respiratory function, walking ability, or both. [118]"}
{"id": "article-25401_113", "title": "Muscular Dystrophy -- Treatment / Management -- Other Interventions", "content": "In addition to pharmacologic intervention,\u00a0comprehensive supportive care\u00a0measures are essential for managing muscular dystrophy. Supportive physiotherapy is crucial, focusing on preventing contractures and prolonging ambulation. [45] The primary goal is to maintain function in unaffected muscle groups, balancing activity to avoid the hastening of muscle fiber breakdown. Strenuous exercise is approached with caution, considering its potential impact. [203]", "contents": "Muscular Dystrophy -- Treatment / Management -- Other Interventions. In addition to pharmacologic intervention,\u00a0comprehensive supportive care\u00a0measures are essential for managing muscular dystrophy. Supportive physiotherapy is crucial, focusing on preventing contractures and prolonging ambulation. [45] The primary goal is to maintain function in unaffected muscle groups, balancing activity to avoid the hastening of muscle fiber breakdown. Strenuous exercise is approached with caution, considering its potential impact. [203]"}
{"id": "article-25401_114", "title": "Muscular Dystrophy -- Treatment / Management -- Other Interventions", "content": "Supportive bracing is implemented to maintain normal function as long as possible. Proper wheelchair seating is essential, and molded ankle-foot orthoses are vital, particularly in stabilizing the gait of those with foot drop. [204] Lightweight plastic ankle-foot orthoses (AFOs) prove highly beneficial for treating footdrop, ensuring individuals with scapuloperoneal muscular dystrophy remain ambulatory for extended periods (\u226540 years). [205] [206] Wheelchairs may be utilized for long-distance travel when necessary, and bracing is tailored for functional purposes, such as preventing tripping or offering support and comfort. [99]", "contents": "Muscular Dystrophy -- Treatment / Management -- Other Interventions. Supportive bracing is implemented to maintain normal function as long as possible. Proper wheelchair seating is essential, and molded ankle-foot orthoses are vital, particularly in stabilizing the gait of those with foot drop. [204] Lightweight plastic ankle-foot orthoses (AFOs) prove highly beneficial for treating footdrop, ensuring individuals with scapuloperoneal muscular dystrophy remain ambulatory for extended periods (\u226540 years). [205] [206] Wheelchairs may be utilized for long-distance travel when necessary, and bracing is tailored for functional purposes, such as preventing tripping or offering support and comfort. [99]"}
{"id": "article-25401_115", "title": "Muscular Dystrophy -- Treatment / Management -- Other Interventions", "content": "Supportive counseling is integral to addressing the psychosocial aspects of the condition. Some forms of muscular dystrophy may experience periods of arrest, allowing patients to remain active with an average life expectancy. [207] Vocational training and supportive counseling are crucial in providing information for planning their future.", "contents": "Muscular Dystrophy -- Treatment / Management -- Other Interventions. Supportive counseling is integral to addressing the psychosocial aspects of the condition. Some forms of muscular dystrophy may experience periods of arrest, allowing patients to remain active with an average life expectancy. [207] Vocational training and supportive counseling are crucial in providing information for planning their future."}
{"id": "article-25401_116", "title": "Muscular Dystrophy -- Treatment / Management -- Other Interventions", "content": "Genetic counseling is recommended, especially for X-linked inheritance cases. [208] Male siblings have a 50% chance of being affected,\u00a0while female siblings have a 50% chance of being carriers. If the affected individual has children, all daughters will be carriers of this X-linked recessive disorder. Genetic counseling should be\u00a0extended to the mother, female siblings, offspring, and maternal relatives.", "contents": "Muscular Dystrophy -- Treatment / Management -- Other Interventions. Genetic counseling is recommended, especially for X-linked inheritance cases. [208] Male siblings have a 50% chance of being affected,\u00a0while female siblings have a 50% chance of being carriers. If the affected individual has children, all daughters will be carriers of this X-linked recessive disorder. Genetic counseling should be\u00a0extended to the mother, female siblings, offspring, and maternal relatives."}
{"id": "article-25401_117", "title": "Muscular Dystrophy -- Treatment / Management -- Other Interventions", "content": "While radiation therapy is not typically the primary treatment modality for muscular dystrophy, it may have a role in managing specific symptoms and complications associated with the disease. It is important to consider\u00a0radiation therapy as part of a multidisciplinary treatment plan and carefully evaluate each patient's individual needs and risks. Further research is needed to better understand the potential benefits and risks of radiation therapy in this patient population.", "contents": "Muscular Dystrophy -- Treatment / Management -- Other Interventions. While radiation therapy is not typically the primary treatment modality for muscular dystrophy, it may have a role in managing specific symptoms and complications associated with the disease. It is important to consider\u00a0radiation therapy as part of a multidisciplinary treatment plan and carefully evaluate each patient's individual needs and risks. Further research is needed to better understand the potential benefits and risks of radiation therapy in this patient population."}
{"id": "article-25401_118", "title": "Muscular Dystrophy -- Differential Diagnosis", "content": "Muscular dystrophy is not always a straightforward diagnosis and can be mistaken for several other diseases with overlapping etiologies. Clinicians must carefully consider and exclude the following conditions in patients presenting with a muscular disorder, as these alternative diagnoses can lead to significant morbidity and mortality: Adrenal insufficiency Electrolyte imbalance: sodium, potassium, and magnesium Hypercalcemia Porphyrias Rabies Complicated migraine Postictal (Todd) paralysis Hypoglycemia Acute spastic paraparesis (a medical emergency) Myasthenia gravis Pancoast tumor Paraneoplastic syndromes", "contents": "Muscular Dystrophy -- Differential Diagnosis. Muscular dystrophy is not always a straightforward diagnosis and can be mistaken for several other diseases with overlapping etiologies. Clinicians must carefully consider and exclude the following conditions in patients presenting with a muscular disorder, as these alternative diagnoses can lead to significant morbidity and mortality: Adrenal insufficiency Electrolyte imbalance: sodium, potassium, and magnesium Hypercalcemia Porphyrias Rabies Complicated migraine Postictal (Todd) paralysis Hypoglycemia Acute spastic paraparesis (a medical emergency) Myasthenia gravis Pancoast tumor Paraneoplastic syndromes"}
{"id": "article-25401_119", "title": "Muscular Dystrophy -- Differential Diagnosis", "content": "An acute onset gait disorder is\u00a0often indicative of\u00a0acute systemic decompensation. A thorough and systematic evaluation\u00a0is essential to exclude\u00a0catastrophic presentations. It\u00a0is not\u00a0recommended to attribute a gait disorder to\u00a0a single disease.\u00a0Gait abnormalities can indicate a severe medical emergency, especially when the problem is associated with any of these additional symptoms: Headache (raised intracranial\u00a0pressure) Nausea or vomiting Decreased alertness Impaired coordination presenting on only one side of the body Recent viral illness/immunization (Guillain-Barr\u00e9 syndrome) Trauma. Questions to consider when evaluating a patient: Are reflexes hypoactive? Hypoactive reflexes\u00a0may suggest myotonic dystrophy, tabes dorsalis, and progressive muscular atrophy. [77] However, diminished reflexes can also be a result of weakness.", "contents": "Muscular Dystrophy -- Differential Diagnosis. An acute onset gait disorder is\u00a0often indicative of\u00a0acute systemic decompensation. A thorough and systematic evaluation\u00a0is essential to exclude\u00a0catastrophic presentations. It\u00a0is not\u00a0recommended to attribute a gait disorder to\u00a0a single disease.\u00a0Gait abnormalities can indicate a severe medical emergency, especially when the problem is associated with any of these additional symptoms: Headache (raised intracranial\u00a0pressure) Nausea or vomiting Decreased alertness Impaired coordination presenting on only one side of the body Recent viral illness/immunization (Guillain-Barr\u00e9 syndrome) Trauma. Questions to consider when evaluating a patient: Are reflexes hypoactive? Hypoactive reflexes\u00a0may suggest myotonic dystrophy, tabes dorsalis, and progressive muscular atrophy. [77] However, diminished reflexes can also be a result of weakness."}
{"id": "article-25401_120", "title": "Muscular Dystrophy -- Differential Diagnosis", "content": "Is there any pain present? Muscle\u00a0weakness and, occasionally, myalgia are typical features of muscle disease.\u00a0Conversely, a short history of painful weakness in adulthood would suggest an inflammatory myositis. [209]", "contents": "Muscular Dystrophy -- Differential Diagnosis. Is there any pain present? Muscle\u00a0weakness and, occasionally, myalgia are typical features of muscle disease.\u00a0Conversely, a short history of painful weakness in adulthood would suggest an inflammatory myositis. [209]"}
{"id": "article-25401_121", "title": "Muscular Dystrophy -- Differential Diagnosis", "content": "Is the problem acute or chronic? The age and rate of progression\u00a0can help determine the type of muscle disease.\u00a0Progressive slow weakness\u00a0without pain from childhood may indicate degenerative muscular dystrophy. Diseases like Dreifuss muscular dystrophy and Bethlem myopathy cause early fixed contractures, representing distinctive features. [3]", "contents": "Muscular Dystrophy -- Differential Diagnosis. Is the problem acute or chronic? The age and rate of progression\u00a0can help determine the type of muscle disease.\u00a0Progressive slow weakness\u00a0without pain from childhood may indicate degenerative muscular dystrophy. Diseases like Dreifuss muscular dystrophy and Bethlem myopathy cause early fixed contractures, representing distinctive features. [3]"}
{"id": "article-25401_122", "title": "Muscular Dystrophy -- Differential Diagnosis", "content": "Is weakness primarily distal or proximal? The distribution of weakness helps define\u00a0the likely type of muscle disease. Proximal arm and leg weakness may be present in limb-girdle muscular dystrophy. [77]", "contents": "Muscular Dystrophy -- Differential Diagnosis. Is weakness primarily distal or proximal? The distribution of weakness helps define\u00a0the likely type of muscle disease. Proximal arm and leg weakness may be present in limb-girdle muscular dystrophy. [77]"}
{"id": "article-25401_123", "title": "Muscular Dystrophy -- Differential Diagnosis", "content": "Is the weakness localized or diffuse? Muscle\u00a0weakness\u00a0could be attributed to various causes, including\u00a0myopathies (eg, dermatomyositis), inflammatory diseases (eg, rheumatoid arthritis), neurologic disorders (eg, Guillain-Barr\u00e9 syndrome), or infections (eg, Lyme disease or trichinosis). [77] Are there any focal neurological lesions? Conditions like myotonic dystrophy, myasthenia gravis, and progressive muscular atrophy may present with partial ptosis. [77]", "contents": "Muscular Dystrophy -- Differential Diagnosis. Is the weakness localized or diffuse? Muscle\u00a0weakness\u00a0could be attributed to various causes, including\u00a0myopathies (eg, dermatomyositis), inflammatory diseases (eg, rheumatoid arthritis), neurologic disorders (eg, Guillain-Barr\u00e9 syndrome), or infections (eg, Lyme disease or trichinosis). [77] Are there any focal neurological lesions? Conditions like myotonic dystrophy, myasthenia gravis, and progressive muscular atrophy may present with partial ptosis. [77]"}
{"id": "article-25401_124", "title": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials", "content": "Radiation therapy (RT) has been studied as a potential treatment for muscular dystrophy, particularly in the context of Duchenne muscular dystrophy.", "contents": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials. Radiation therapy (RT) has been studied as a potential treatment for muscular dystrophy, particularly in the context of Duchenne muscular dystrophy."}
{"id": "article-25401_125", "title": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials", "content": "One study published in the Journal of Radiation Research in 2018 evaluated the effects of low-dose whole-body irradiation in a mouse model of DMD. The study found that low-dose irradiation improved muscle strength and reduced muscle damage in the mice, suggesting that RT may have therapeutic potential in the treatment of DMD.", "contents": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials. One study published in the Journal of Radiation Research in 2018 evaluated the effects of low-dose whole-body irradiation in a mouse model of DMD. The study found that low-dose irradiation improved muscle strength and reduced muscle damage in the mice, suggesting that RT may have therapeutic potential in the treatment of DMD."}
{"id": "article-25401_126", "title": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials", "content": "Another study published in the journal Frontiers in Oncology in 2019 reviewed the available literature on the use of RT for muscular dystrophy. The authors found that while there is limited data on the effectiveness of RT for muscular dystrophy, early studies suggest that low-dose RT may be a promising treatment option. However, more research is needed to determine the optimal dose and timing of RT for this condition.", "contents": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials. Another study published in the journal Frontiers in Oncology in 2019 reviewed the available literature on the use of RT for muscular dystrophy. The authors found that while there is limited data on the effectiveness of RT for muscular dystrophy, early studies suggest that low-dose RT may be a promising treatment option. However, more research is needed to determine the optimal dose and timing of RT for this condition."}
{"id": "article-25401_127", "title": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials", "content": "Currently, there are no ongoing clinical trials specifically evaluating the use of RT for muscular dystrophy. However, there are ongoing trials exploring gene therapy and other novel approaches for the treatment of DMD, which may have implications for the use of RT in the future.", "contents": "Muscular Dystrophy -- Pertinent Studies and Ongoing Trials. Currently, there are no ongoing clinical trials specifically evaluating the use of RT for muscular dystrophy. However, there are ongoing trials exploring gene therapy and other novel approaches for the treatment of DMD, which may have implications for the use of RT in the future."}
{"id": "article-25401_128", "title": "Muscular Dystrophy -- Prognosis", "content": "Individuals\u00a0with dystrophies\u00a0involving\u00a0significant heart involvement may\u00a0still have\u00a0nearly average life spans,\u00a0given diligent\u00a0monitoring and aggressive treatment of cardiac issues. [90] Long-term care focuses on preserving ambulation and closely tracking any signs of cardiopulmonary complications.\u00a0Despite notable progress in muscular dystrophy treatment, the disease remains\u00a0incurable and\u00a0lacks preventative measures. Most patients succumb to cardiopulmonary failure before reaching 30. [210] Proper care, however, can enhance the quality of life for affected individuals.", "contents": "Muscular Dystrophy -- Prognosis. Individuals\u00a0with dystrophies\u00a0involving\u00a0significant heart involvement may\u00a0still have\u00a0nearly average life spans,\u00a0given diligent\u00a0monitoring and aggressive treatment of cardiac issues. [90] Long-term care focuses on preserving ambulation and closely tracking any signs of cardiopulmonary complications.\u00a0Despite notable progress in muscular dystrophy treatment, the disease remains\u00a0incurable and\u00a0lacks preventative measures. Most patients succumb to cardiopulmonary failure before reaching 30. [210] Proper care, however, can enhance the quality of life for affected individuals."}
{"id": "article-25401_129", "title": "Muscular Dystrophy -- Prognosis", "content": "Duchenne muscular dystrophy\u00a0typically results in a life expectancy of\u00a0around 20 years,\u00a0with a fatal outcome\u00a0in 100% of cases. [210] Children\u00a0affected by Duchenne muscular dystrophy usually succumb to other pulmonary or cardiac causes,\u00a0with\u00a0death\u00a0occurring\u00a0in\u00a0the late teens. Only 25% live to age 21. [211] Walker-Warburg syndrome, the most severe congenital muscular dystrophy,\u00a0leads to death by\u00a01 year of age. [211] Becker dystrophy is associated with a reduced life expectancy, but most individuals survive into the fourth or fifth decade. [211] Life expectancy is average in patients with facioscapulohumeral dystrophy. [211]", "contents": "Muscular Dystrophy -- Prognosis. Duchenne muscular dystrophy\u00a0typically results in a life expectancy of\u00a0around 20 years,\u00a0with a fatal outcome\u00a0in 100% of cases. [210] Children\u00a0affected by Duchenne muscular dystrophy usually succumb to other pulmonary or cardiac causes,\u00a0with\u00a0death\u00a0occurring\u00a0in\u00a0the late teens. Only 25% live to age 21. [211] Walker-Warburg syndrome, the most severe congenital muscular dystrophy,\u00a0leads to death by\u00a01 year of age. [211] Becker dystrophy is associated with a reduced life expectancy, but most individuals survive into the fourth or fifth decade. [211] Life expectancy is average in patients with facioscapulohumeral dystrophy. [211]"}
{"id": "article-25401_130", "title": "Muscular Dystrophy -- Complications", "content": "Some complications of muscular dystrophy include: Bone demineralization: Reduced mobilization and immobilization contribute to osteopenia and osteoporosis, leading to an increased risk of fractures and scoliosis. [212] Cardiopulmonary disease: Regular monitoring is essential to address secondary complications such as cardiopulmonary disease or cardiac failure resulting from cardiomyopathy. [212] Disability: Muscular injuries and contractures can lead to disability, necessitating dependence on walking aids like wheelchairs. [212] Anesthesia Risk: Patients with muscular dystrophy may experience challenges with general anesthesia and typically require intensive postoperative observation for optimal care. [212]", "contents": "Muscular Dystrophy -- Complications. Some complications of muscular dystrophy include: Bone demineralization: Reduced mobilization and immobilization contribute to osteopenia and osteoporosis, leading to an increased risk of fractures and scoliosis. [212] Cardiopulmonary disease: Regular monitoring is essential to address secondary complications such as cardiopulmonary disease or cardiac failure resulting from cardiomyopathy. [212] Disability: Muscular injuries and contractures can lead to disability, necessitating dependence on walking aids like wheelchairs. [212] Anesthesia Risk: Patients with muscular dystrophy may experience challenges with general anesthesia and typically require intensive postoperative observation for optimal care. [212]"}
{"id": "article-25401_131", "title": "Muscular Dystrophy -- Deterrence and Patient Education", "content": "Deterrence and patient education for individuals with muscular dystrophy involves a comprehensive approach to prevent complications and enhance overall well-being. Key aspects include promoting appropriate physical activity, orthopedic care for scoliosis, cardiopulmonary monitoring, nutritional guidance, respiratory care, fall prevention strategies, genetic counseling, and medication management education.", "contents": "Muscular Dystrophy -- Deterrence and Patient Education. Deterrence and patient education for individuals with muscular dystrophy involves a comprehensive approach to prevent complications and enhance overall well-being. Key aspects include promoting appropriate physical activity, orthopedic care for scoliosis, cardiopulmonary monitoring, nutritional guidance, respiratory care, fall prevention strategies, genetic counseling, and medication management education."}
{"id": "article-25401_132", "title": "Muscular Dystrophy -- Deterrence and Patient Education", "content": "Emotional support through engagement with support groups and counseling services is also emphasized. Regular medical check-ups and open communication with healthcare providers are crucial in ongoing monitoring and addressing emerging concerns, allowing individuals to actively participate in their care and optimize their quality of life.", "contents": "Muscular Dystrophy -- Deterrence and Patient Education. Emotional support through engagement with support groups and counseling services is also emphasized. Regular medical check-ups and open communication with healthcare providers are crucial in ongoing monitoring and addressing emerging concerns, allowing individuals to actively participate in their care and optimize their quality of life."}
{"id": "article-25401_133", "title": "Muscular Dystrophy -- Pearls and Other Issues", "content": "Key facts to keep in mind about\u00a0muscular dystrophies\u00a0are\u00a0presented below.", "contents": "Muscular Dystrophy -- Pearls and Other Issues. Key facts to keep in mind about\u00a0muscular dystrophies\u00a0are\u00a0presented below."}
{"id": "article-25401_134", "title": "Muscular Dystrophy -- Pearls and Other Issues -- Duchenne muscular dystrophy", "content": "Genetics: X-linked recessive disorder caused by mutations in the DMD gene. Onset: Typically early childhood (around 3 to 5). Clinical features: Progressive muscle weakness, particularly in the pelvic and shoulder girdle muscles. Diagnostic tests: Elevated\u00a0CK levels, genetic testing for DMD gene mutations. Prognosis: Rapid progression, wheelchair dependence by adolescence, cardiopulmonary complications.", "contents": "Muscular Dystrophy -- Pearls and Other Issues -- Duchenne muscular dystrophy. Genetics: X-linked recessive disorder caused by mutations in the DMD gene. Onset: Typically early childhood (around 3 to 5). Clinical features: Progressive muscle weakness, particularly in the pelvic and shoulder girdle muscles. Diagnostic tests: Elevated\u00a0CK levels, genetic testing for DMD gene mutations. Prognosis: Rapid progression, wheelchair dependence by adolescence, cardiopulmonary complications."}
{"id": "article-25401_135", "title": "Muscular Dystrophy -- Pearls and Other Issues -- Becker muscular dystrophy", "content": "Genetics: X-linked recessive disorder caused by mutations in the DMD gene. Onset: Later than DMD, often in adolescence or adulthood. Clinical features: Similar to DMD but with milder symptoms and slower progression. Diagnostic tests: Elevated CK levels, genetic testing for DMD gene mutations. Prognosis: Variable, some individuals may remain ambulatory into adulthood.", "contents": "Muscular Dystrophy -- Pearls and Other Issues -- Becker muscular dystrophy. Genetics: X-linked recessive disorder caused by mutations in the DMD gene. Onset: Later than DMD, often in adolescence or adulthood. Clinical features: Similar to DMD but with milder symptoms and slower progression. Diagnostic tests: Elevated CK levels, genetic testing for DMD gene mutations. Prognosis: Variable, some individuals may remain ambulatory into adulthood."}
{"id": "article-25401_136", "title": "Muscular Dystrophy -- Pearls and Other Issues -- Myotonic dystrophy", "content": "Genetics: Autosomal dominant disorder, involving DMPK gene (DM1) or CNBP gene (DM2). Clinical features: Myotonia, muscle wasting, cataracts, cardiac conduction abnormalities. Diagnostic tests: Genetic testing for CTG repeats (DM1) or CCTG repeats (DM2). Prognosis: Variable, with a range of severity; may involve multiple systems.", "contents": "Muscular Dystrophy -- Pearls and Other Issues -- Myotonic dystrophy. Genetics: Autosomal dominant disorder, involving DMPK gene (DM1) or CNBP gene (DM2). Clinical features: Myotonia, muscle wasting, cataracts, cardiac conduction abnormalities. Diagnostic tests: Genetic testing for CTG repeats (DM1) or CCTG repeats (DM2). Prognosis: Variable, with a range of severity; may involve multiple systems."}
{"id": "article-25401_137", "title": "Muscular Dystrophy -- Pearls and Other Issues -- Facioscapulohumeral muscular dystrophy", "content": "Genetics: Autosomal dominant disorder, involving DUX4 gene. Clinical features: Progressive weakness in face, shoulders, and upper arms. Diagnostic tests: Genetic testing for DUX4 gene mutations. Prognosis: Variable, may involve asymmetric muscle weakness.", "contents": "Muscular Dystrophy -- Pearls and Other Issues -- Facioscapulohumeral muscular dystrophy. Genetics: Autosomal dominant disorder, involving DUX4 gene. Clinical features: Progressive weakness in face, shoulders, and upper arms. Diagnostic tests: Genetic testing for DUX4 gene mutations. Prognosis: Variable, may involve asymmetric muscle weakness."}
{"id": "article-25401_138", "title": "Muscular Dystrophy -- Pearls and Other Issues -- Limb-Girdle muscular dystrophy", "content": "Genetics: Heterogeneous group, both autosomal dominant and recessive forms. Clinical features: Proximal muscle weakness in the pelvic and shoulder girdles. Diagnostic tests: Genetic testing for various associated genes associated. Prognosis: Variable, depending on the specific subtype.", "contents": "Muscular Dystrophy -- Pearls and Other Issues -- Limb-Girdle muscular dystrophy. Genetics: Heterogeneous group, both autosomal dominant and recessive forms. Clinical features: Proximal muscle weakness in the pelvic and shoulder girdles. Diagnostic tests: Genetic testing for various associated genes associated. Prognosis: Variable, depending on the specific subtype."}
{"id": "article-25401_139", "title": "Muscular Dystrophy -- Pearls and Other Issues -- Emery-Dreifuss muscular dystrophy", "content": "Genetics: X-linked or autosomal dominant, involving EMD and LMNA genes. Clinical features: Early contractures, muscle wasting, cardiac conduction abnormalities. Diagnostic tests: Genetic testing for EMD and LMNA gene mutations. Prognosis: Cardiac complications can be life-threatening.", "contents": "Muscular Dystrophy -- Pearls and Other Issues -- Emery-Dreifuss muscular dystrophy. Genetics: X-linked or autosomal dominant, involving EMD and LMNA genes. Clinical features: Early contractures, muscle wasting, cardiac conduction abnormalities. Diagnostic tests: Genetic testing for EMD and LMNA gene mutations. Prognosis: Cardiac complications can be life-threatening."}
{"id": "article-25401_140", "title": "Muscular Dystrophy -- Enhancing Healthcare Team Outcomes", "content": "Adolescents with muscular dystrophy\u00a0require a comprehensive\u00a0interprofessional plan of care that addresses various aspects of their health. This includes carefully considering potential\u00a0cardiac and\u00a0respiratory issues, monitoring\u00a0weight changes, addressing concerns related to constipation, addressing rehabilitative and developmental difficulties, attending to psychosocial needs, and managing neurologic and orthopedic problems. [212]", "contents": "Muscular Dystrophy -- Enhancing Healthcare Team Outcomes. Adolescents with muscular dystrophy\u00a0require a comprehensive\u00a0interprofessional plan of care that addresses various aspects of their health. This includes carefully considering potential\u00a0cardiac and\u00a0respiratory issues, monitoring\u00a0weight changes, addressing concerns related to constipation, addressing rehabilitative and developmental difficulties, attending to psychosocial needs, and managing neurologic and orthopedic problems. [212]"}
{"id": "article-25401_141", "title": "Muscular Dystrophy -- Enhancing Healthcare Team Outcomes", "content": "Implementing a standardized approach for collecting and sharing data is crucial for optimizing overall performance in various healthcare programs, sites, and organizations. [45] This approach contributes to improved quality of care and reduces disparities in healthcare delivery through the standardization of care practices. Clinicians and healthcare institutions are actively involved in promoting early diagnosis of muscular dystrophy, and a strategic indicator for evaluation could be the percentage of patients undergoing genetic testing or being offered such testing. Clearly defining care goals from the outset provides a framework for other team members to establish their success indicators more precisely. [45]", "contents": "Muscular Dystrophy -- Enhancing Healthcare Team Outcomes. Implementing a standardized approach for collecting and sharing data is crucial for optimizing overall performance in various healthcare programs, sites, and organizations. [45] This approach contributes to improved quality of care and reduces disparities in healthcare delivery through the standardization of care practices. Clinicians and healthcare institutions are actively involved in promoting early diagnosis of muscular dystrophy, and a strategic indicator for evaluation could be the percentage of patients undergoing genetic testing or being offered such testing. Clearly defining care goals from the outset provides a framework for other team members to establish their success indicators more precisely. [45]"}
{"id": "article-25401_142", "title": "Muscular Dystrophy -- Enhancing Healthcare Team Outcomes", "content": "All healthcare team members must remain well-informed about a patient's condition, fostering effective communication among team members to utilize each profession's expertise. This patient-centered communication approach prioritizes the individual over the disease and can include sharing information about support groups or informative websites. Encouraging patients to participate actively in their care is essential, emphasizing their role in the treatment process. It is crucial to empower patients and their families, moving away from a passive mindset and recognizing their active involvement in their healthcare journey. [212]", "contents": "Muscular Dystrophy -- Enhancing Healthcare Team Outcomes. All healthcare team members must remain well-informed about a patient's condition, fostering effective communication among team members to utilize each profession's expertise. This patient-centered communication approach prioritizes the individual over the disease and can include sharing information about support groups or informative websites. Encouraging patients to participate actively in their care is essential, emphasizing their role in the treatment process. It is crucial to empower patients and their families, moving away from a passive mindset and recognizing their active involvement in their healthcare journey. [212]"}
{"id": "article-25401_143", "title": "Muscular Dystrophy -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Muscular Dystrophy -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}